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ABSTRACT 
  
Hyperglycemia during pregnancy is associated with adverse outcomes for both 
mother and offspring.  In order to facilitate glucose delivery to the fetus, insulin 
resistance increases as gestation progresses which results in hyperglycemia if the 
mother’s body is unable to compensate by producing adequate insulin in response to 
these changes in glucose metabolism.  Evidence suggests that calcidiol (vitamin D) 
influences insulin sensitivity and glucose metabolism in the non-pregnant population yet 
there are inconsistent findings on the effects of calcidiol on maternal glucose levels 
during pregnancy.  A secondary analysis was completed on a de-identified data set.  The 
original prospective study included a convenience sample of 52 nulliparous women from 
a community in the upper Midwestern United States.  Serum vitamin D levels were 
obtained through laboratory measures at three predetermined points during pregnancy.  
Medical record abstraction provided blood glucose levels in mid-pregnancy and height 
and weight to calculate body mass index (BMI) at the beginning of pregnancy.  Eighty-
one percent of the participants had hypovitaminosis-D at some point during pregnancy 
and 67% had hypovitaminosis-D at all three points during pregnancy.  Multiple 
regression analysis was completed to examine the relationship between calcidiol levels 
and blood glucose levels.  A t-test was performed to look for a difference between two 
groups, those with adequate calcidiol levels and those with inadequate serum calcidiol 
levels.  There was no evidence of a statistically significant relationship between calcidiol 
xvi 
levels at any of the three points and the blood glucose levels when controlling for the 
known confounding variables of BMI and age (R square .084, .071, and .075 
respectively).  The high percentage of hypovitaminosis-D was believed to result in 
inadequate variance in this sample to show a difference, if one does exist.  There was a 
statistically significant correlation among the three calcidiol levels (p < .05).  There was a 
statistically significant inverse relationship between BMI and calcidiol levels in early 
pregnancy (p < .05) and mid-pregnancy (p < .05).  These findings suggest that many 
women have hypovitaminosis-D in pregnancy, these levels are not improving during 
pregnancy, and that women with a higher BMI may need additional vitamin D during 
pregnancy.     
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CHAPTER I 
INTRODUCTION 
Hyperglycemia during pregnancy is associated with adverse outcomes for both 
mothers and offspring (Pridjian & Benjamin, 2010) creating the need for interventions 
which can reduce the harm from this condition.  Research evidence suggests that vitamin 
D influences glucose metabolism in the non-pregnant population (Forouhi, Luan, Cooper, 
Boucher & Wareham, 2008; Hirani, 2011) and possibly in the pregnant population (Wei, 
Qi, Luo & Fraser, 2013).  More specifically, hypovitaminosis-D has been associated with 
impaired glucose metabolism in conditions such as in type 2 diabetes (Alfonso, Liao, 
Busta & Poretsky, 2009; Mathieu, Gysemans, Giulietti & Bouillon, 2005; Pittas et al., 
2006; Tohidi et al., 2013).  There is a need to determine whether vitamin D similarly 
influences glucose metabolism in pregnancy (Alzaim & Wood, 2013; McLeod et al., 
2011).   
This chapter begins with a brief overview of the adaptations of glucose 
metabolism in pregnancy and maternal hyperglycemia in pregnancy.  It will be followed 
by information on vitamin D metabolism, hypovitaminosis-D, and vitamin D in pregnant 
women.  Last, information specific to this study will be presented including the purpose 
statement, hypothesis, problem statement, research questions, theoretical framework, 
significance, and assumptions.    
 
2 
Adaptations of Glucose Metabolism in Pregnancy 
Significant alterations occur in maternal physiology during pregnancy (Torgerson 
& Curran, 2006).  The placental hormones reprogram the maternal physiology to meet 
the needs of the fetus and this includes a progressive increase in insulin resistance 
(Barbour et al., 2007).  The insulin resistance subsequently triggers the β-cells of the 
pancreas to increase insulin production in order to maintain glucose homeostasis 
(Evensen, 2012; Jelsma et al., 2013).  In some cases, the pancreatic β-cells are not able to 
adequately increase production which results in impaired glucose metabolism and 
hyperglycemia (Gabbe et al., 2012, p. 892).  Since the fetus obtains glucose from the 
mother through the placenta, the adverse outcomes of maternal hyperglycemia during 
pregnancy involve both the woman and the baby (Evensen, 2012; Lehnen, Zechner & 
Haaf, 2013).   
During pregnancy, insulin resistance progressively develops in the woman to 
ensure the fetus is supplied with adequate glucose (Evenson, 2012).  As the pregnancy 
progresses, there is a gradual increase in post-prandial blood glucose levels  (Gabbe et al., 
2012, p. 888) and the pancreatic β-cells need to respond by producing more insulin to 
prevent hyperglycemia (McLeod et al., 2012).  However, for some women, the β-cells of 
the pancreas do not adequately increase the production of insulin to compensate (Jelsma 
et al., 2013) which results in impaired glucose tolerance (Senti, Thiele & Anderson, 
2012).  These changes can be sufficiently diabetogenic for some of these women to result 
in gestational diabetes (Senti et al., 2012). 
3 
Maternal Hyperglycemia in Pregnancy 
Normally, pregnant women develop some insulin resistance during the second 
and the third trimesters (McLeod et al., 2012) which can lead to hyperglycemia.  Even 
mildly increased maternal blood glucose levels can result in higher glucose delivery that 
can affect the fetus (Fetita et al., 2006).  The resulting hyperglycemia can have serious 
health consequences for the mother and her children (Flack, Ross, Ho, & McElduff, 
2010; Santamari, Cignini, Trapanese, & Bonalumi, 2011).  Women who develop 
hyperglycemia during pregnancy are at increased risk for early, induced labor, difficult 
labor, and operative delivery (vacuum, forceps, or cesarean).  Infants of mothers with 
hyperglycemia are at increased risk for macrosomia, birth injury such as shoulder 
dystocia or fractured clavicle, and medical complications after birth including 
hypoglycemia, polycythemia, hypocalcemia, respiratory distress syndrome, and 
hyperbilirubinemia (Santamari, Cignin, Trapanese, & Bonalumi, 2011).  These conditions 
may require more medical interventions including costly care in a neonatal intensive care 
unit (Riskin-Mashiah, Younes, Damti & Auslender, 2009) and separation of infants from 
their mothers in the critical first hours of life.  Long-term effects exist beyond the 
newborn period and may contribute to the increasing rates of obesity and diabetes 
(Ryan, 2013).   
The most commonly known condition which causes hyperglycemia in pregnancy 
is gestational diabetes mellitus which affects 2-13% of all pregnancies, depending upon 
the population group studied (Poel et al., 2012).  Gestational diabetes mellitus is one of 
the most common complications in pregnancy (Macones, 2012; Poel et al., 2012) and the 
prevalence is rising worldwide (Lehnen, Zechner & Haaf, 2013).  In addition, gestational 
4 
diabetes markedly increases the risk of a woman developing type 2 diabetes in later life 
(Makgoba et al., 2011).    
Gestational diabetes mellitus has been extensively researched in the professional 
literature for many years.  Less has been written about blood glucose levels in the upper 
limit of normal but not over the threshold for a diagnosis of GDM.  Many healthy women 
fit into this category during pregnancy.  Since there is a paucity of scientific literature on 
hyperglycemia during pregnancy for healthy women, some of the research on GDM will 
be considered as proxy to hyperglycemia in this study to gain insight into the effects of 
hyperglycemia in pregnancy.   
 One major study to fill the knowledge gap on the link between mild, maternal 
hyperglycemia and pregnancy outcomes was the Hyperglycemia and Adverse Pregnancy 
Outcome (HAPO) study which involved 15 centers in 9 countries and over 25,000 
pregnant women (Coustan, Lowe, Metzger, & Dyer, 2010; Leary, Pettitt & Javanovic, 
2010).  The HAPO study revealed that maternal hyperglycemia at levels less than 
required for a diagnosis of GDM do pose a risk for adverse outcomes for the offspring 
(Coustan et al., 2010; The HAPO Study Cooperative Research Group, 2008).  The HAPO 
study was powered to detect the primary outcomes of neonatal hypoglycemia, 
hyperinsulinemia and macrosomia in the infant, and primary cesarean birth in the 
mothers (Coustan et al., 2010).  The secondary outcomes of the HAPO study included 
birth at <37 weeks gestation, birth injury (such as shoulder dystocia), hyperbilirubinemia, 
and need for neonatal intensive care (Coustan et al., 2010; HAPO Study Cooperative 
Research Group, 2002).  These findings demonstrate the harm which can result from 
maternal hyperglycemia during pregnancy supporting the need for prevention strategies. 
5 
Brief Overview of Vitamin D Metabolism 
Vitamin D comes from two sources which are identified as vitamin D2 
(ergocalciferol) or vitamin D3 (cholecaliciferol).  Vitamin D is unique in that it is 
considered both a vitamin and a pro-hormone with a vitamin D receptor found in nearly 
every cell in the human body (Holick, 2005; Lips, 2006; McCullough, 2007; Pittas & 
Dawson-Hughes, 2010).  Vitamin D is synthesized from direct sunlight on exposed skin 
or obtained from supplements, fortified foods, or one of the few foods which naturally 
contain vitamin D (Thorne-Lyman & Fawzi, 2012; Specker, 2004).  Synthesis of vitamin 
D in the skin can be affected by latitude, season of the year, cloud cover, pollution, age, 
body mass index (BMI), the amount of melanin in the skin, ethnicity, genetics, renal 
function and liver function (Collins-Fulea, Klima & Wegienka, 2012; Holmes, Barnes, 
Alexander, McFaul, & Wallace, 2009; Prentice, 2008; Wicherts et al., 2011).   
Hypovitaminosis-D 
Vitamin D deficiency is a problem worldwide (Ginde, Sullivan, Mansbach & 
Camargo, 2010; Hanley & Davison, 2005).  Hypovitaminosis-D affects nearly 41.6% of 
the adults in the United States according to the National Health and Nutrition 
Examination Survey (NHANES) report (Forrest & Stuhledreher, 2011).  
Hypovitaminosis-D is often a problem for women, especially those who live in Northern 
latitudes, have darkly pigmented skin, or those whose clothing prohibits direct sunlight 
on exposed skin (Holick & Chen, 2008).  Maghbooli, Hossein-nezhad, Karimi, Shafaei 
and Larijani (2008) reported that hypovitaminosis-D was found in 70.6% of the pregnant 
women in their research in Iran.  In Oakland, California, 54.4% of pregnant women were 
found to have hypovitaminosis-D (Dror, King, Durand, & Allen, 2011).  In the United 
6 
States, 69% of pregnant women were found to have hypovitaminosis-D from a secondary 
analysis of the National Health and Nutrition Examination Survey (NHANES) from 2001 
– 2006.  The NHANES study collected data on women of childbearing age which ranged 
from 13-44 years so this data set included younger pregnant women (Ginde, Sullivan, 
Mansbach & Camargo, 2010).  Ginde et al. (2010) reported that younger pregnant women 
were more frequently nonwhite (57%), lower socioeconomic status, and not using any 
vitamin D supplements and all of these factors increased their risk of hypovitaminosis-D 
in pregnancy.  They further reported the novel finding of similar rates of 
hypovitaminosis-D in Hispanic and non-Hispanic blacks which they concluded was likely 
to decreased synthesis of vitamin D in the skin due to the levels of melanin.  Wagner et 
al. (2015) found the mean serum calcidiol level in early pregnancy was 58 nmol/L (5 – 
185 nmol/L) in a sample of over 400 women.    
Calcidiol in Pregnant Women 
Calcidiol levels are unlikely to change in pregnancy unless there is an increase in 
synthesis (cholecalciferol from the sun; D3) or intake from plants and absorbed through 
the gut (ergocalciferol, D2), or intake from supplements (either D2 or D3) (Gabbe et al., 
2012, p. 59).  The active metabolite of vitamin D, calcitriol, progressively increases 
during pregnancy (Barrett & McElduff, 2010; Hollis, Johnson, Hulsey, Ebeling, & 
Wagner, 2011; Holmes et al., 2009).  Holmes et al. (2009) suggest that there is an 
increased demand for vitamin D during pregnancy to support these higher levels of 
calcitriol.  Hollis et al. (2011) found that women with higher intake of oral vitamin D 
supplements had higher calcitriol levels as pregnancy progressed when compared with 
women who had lower intake of vitamin D supplements.   
7 
Calcidiol and Glucose Metabolism 
Insufficient vitamin D may be associated with insulin resistance with the resulting 
hyperglycemia.  Serum calcidiol is the usual measure for vitamin D and low levels may 
be a risk factor for impaired glucose metabolism leading to hyperglycemia (Forouhi et 
al., 2008; Wang et al., 2012).  Several researcher have reported an association between 
calcidiol levels and glucose metabolism (Chiu, Chu, Go & Saad, 2004;  Forouhi et al., 
2012; Moreira & Hamadeh, 2010; Holick, 2005; Pittas & Dawson-Hughes, 2010; 
Palomer, Gonzalez-Clemente, Blanco-Vaca & Mauricio, 2008; Song & Manson, 2010).  
McLeod et al. (2011) found an association between serum calcidiol levels and pancreatic 
β-cell function linking vitamin D with an effect on insulin production and glucose 
metabolism.  Kayaniyil et al. (2011) reported higher calcidiol levels independently 
predict improved pancreatic β-cell function.  These studies illustrate the emerging 
evidence on the positive influence of vitamin D on glucose metabolism. 
Serum Calcidiol and Glucose Metabolism in Pregnancy 
Vitamin D may have the potential to positively influence glucose metabolism 
during pregnancy.  A limited number of researchers have studied the relationship 
between serum calcidiol levels in the first trimester and impaired glucose metabolism in 
pregnancy (Baker et al., 2012; Fernandez-Alfonso et al., 2012; Makgoba et al., 2011; 
Tomedi et al., 2013).  Others have examined the relationship between serum vitamin D 
levels in the second trimester and the blood glucose levels in mid-pregnancy (Burris et 
al., 2012; Clifton–Bligh et al., 2008; Maghbooli et al., 2008; Parlea et al., 2012; 
Soheilykhah et al., 2010; Zhang et al., 2008).  Two studies were found which looked at 
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serum vitamin D level in the third trimester and glucose metabolism in pregnancy 
(Farrant et al., 2009; Lau et al., 2011).   
More specifically, some researchers have found an inverse relationship between 
serum calcidiol levels and maternal blood glucose levels in pregnancy.  Burris et al. 
(2012) examined second trimester calcidiol and blood sugar levels when using a one-hour 
glucose screening test.  Their results indicated that hypovitaminosis-D may increase the 
risk of impaired glucose metabolism.  A few observational studies indicated a significant 
difference in serum calcidiol in women with impaired glucose metabolism versus normal 
glucose tolerance (Clifton-Bligh, 2008; Maghbooli, 2007; Soheilykhah, 2010; Zhang, 
2008) and reported a correlation between maternal vitamin D status and impaired glucose 
metabolism.  Hypovitaminosis-D has been associated with impaired glucose metabolism 
in both pregnant and non-pregnant humans (Alzaim & Wood, 2013).   Pregnant women 
with hypovitaminosis-D may be at increased risk for hyperglycemia (Shin, Choi, 
Longtine & Nelson, 2010) but it still is not clear if this is a causal relationship (Poel et al., 
2012).  Therefore, a need exists to further explore the association between vitamin D and 
glucose metabolism.      
Purpose Statement 
The purpose of this study was to determine the relationship between calcidiol 
levels collected in early, mid, and late pregnancy and blood glucose levels in mid 
pregnancy in a sample of women in an upper Midwestern region of the United States.  A 
quantitative, correlational design was used in a secondary analysis to ask new questions 
of an existing data set.  According to Pridjian and Benjamin, (2010), hyperglycemia 
during pregnancy is associated with adverse outcomes for both the mother and baby.  It is 
9 
known that calcidiol influences glucose metabolism in the non-pregnant population 
(Alfonso et al., 2009; Mathieu et al., 2005; Pittas et al., 2006; Tohidi et al., 2013) and this 
study investigated the influence of calcidiol on glucose metabolism in the pregnant 
population.  The significance of this relationship is that it may inform an understanding 
of the effect of calcidiol on glucose metabolism in pregnancy.  By identifying the 
correlation between calcidiol and glucose levels, there is the potential to mitigate 
hyperglycemia in pregnancy and improve the health of infants and mothers.  
Research Hypothesis 
The working hypothesis for this study was that there is an inverse relationship 
between calcidiol during pregnancy and mid pregnancy blood glucose levels. 
Research Questions 
1. Is there a correlation between the calcidiol level at 10-14 weeks gestation and 
the blood glucose (BG) level at 24-28 weeks gestation when controlling for the known 
confounding variables of age and pre-pregnancy body mass index (BMI)? 
2. Is there a correlation between calcidiol level at 22-26 weeks gestation and the 
BG level at 24-28 weeks gestation when controlling for the known confounding variables 
of age and BMI? 
3. Is there a correlation between the calcidiol level at 32-36 weeks gestation and 
the BG level at 24-28 weeks gestation when controlling for the known confounding 
variables of age and BMI? 
Problem Statement 
Although studies are emerging which support an association between vitamin D 
levels and impaired glucose metabolism (Alzaim & Wood, 2013), there are inconsistent 
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findings on the effects of vitamin D and maternal glucose levels during pregnancy.  It is 
known that many women have hypovitaminosis-D during pregnancy (Aslam, Masood, 
Sattar, & Qudsia, 2012) and that some women develop impaired glucose metabolism in 
pregnancy (Davenport, Campbell, & Mottola, 2010; Evenson, 2012; Hunt & Schuller, 
2007; Veeraswamy, Vijayam, Gupta, & Kapur, 2012).  A need exists to learn more about 
the effect of vitamin D on maternal glucose levels in pregnant women (Joergensen, 
Lamont & Torloni, 2014; Senti, Thiele, & Anderson, 2013).  Addressing this gap in 
knowledge may contribute to strategies which could improve glucose metabolism in 
pregnancy.  
Theoretical Framework 
The Neuman Systems Model (NSM) provides a unifying focus for a wide range 
of health concerns by using open systems-based approach (Neuman, 2011).  The Neuman 
model is concerned with the patient’s reaction and response to environmental stressors, 
both external and internal (Gigliotti, 2003).  According to the NSM, clients who need 
nursing care are people dealing with stressors or anticipating stressors (such as 
physiologic variables) in their environment.  The model defines universal, basic survival 
factors which include genetic factors and the innate strengths and weaknesses within the 
client system (Meleis, 2012).  According to Neuman and Reed (2007), the NSM is 
comprised of several key components that provide the mechanism for attaining optimal 
wellness.  These components include five variables within the client’s system 
(physiological, psychological, developmental, sociocultural, and spiritual), the interaction 
with the environment (internal, external, or created), and three prevention levels. The 
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model also includes lines of resistance and lines of defense (flexible and normal) as part 
of the interaction (Gigliotti, 2003). 
The normal line of defense is the inner boundary of the client system, defines its 
integrity and stability, and is used to measure variance from wellness (Neuman, 2005).  
The flexible line of defense is the outer boundary of the client system and functions as a 
buffer by preventing stressor invasion of the client’s system (Neuman, 2005).  The 
protective internal and external mechanisms which work to stabilize the client system and 
maintain wellness are the lines of resistance and support the basic structure of the client, 
such as the immune system (Neuman, 2005).  The metabolic demands of pregnancy are 
an internal, physiological stressor which can cause imbalance from insulin resistance and 
hyperglycemia which results in impaired glucose metabolism.  In Neuman’s model, the 
goal of nursing is to prevent or correct instability (Meleis, 2010).  Using the NSM, 
interventions by the nurse include helping the individual patient identify barriers to 
change and helping her discover ways to improve her diet and activity (external 
environment) to balance maintain normal blood glucose levels (internal environment).  
This will reduce the physiological stressors in her internal environment, restore health, 
and improve the outcome of the pregnancy for both her and her baby.   
The diagnosis of impaired glucose metabolism creates a psychological stressor.  
The woman may feel overwhelmed and fearful for herself and her baby.  Persson, 
Winkvist and Mogren (2010) found that women with this condition expressed a change in 
self-image and a loss of normalcy.  Using the NSM, the nurse can enter into a bonding 
partnership by providing individualized attention for the client, compassionate care, 
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specific education, and encouragement (Neuman & Reed, 2007).  Such a partnership can 
reduce the psychological stressors to restore well-being. 
Significance of Study 
Since hyperglycemia during pregnancy results in long-term health consequences 
for both mother and baby (Pridjian & Benjamin, 2010), there is a need for interventions 
which can improve glucose metabolism during pregnancy.  Hypovitaminosis-D has been 
associated with impaired glucose metabolism in the non-pregnant population (Parlea et 
al., 2011).  Since hypovitaminosis-D occurs in 70.6% of pregnancies (Maghbooli et al., 
2008), a correlation between hypovitaminosis-D in pregnancy and maternal 
hyperglycemia would be noteworthy and may support vitamin D supplementation as an 
intervention to improve glucose metabolism in pregnancy (Tomedi, Simhan, & Bodnar, 
2013).  The goal of this research was to contribute to the science by identifying if there is 
an inverse relationship between maternal calcidiol status and blood glucose levels at mid-
pregnancy.  If such a relationship exists, the next step would be to determine therapeutic 
levels for maternal serum vitamin D for optimal glucose homeostasis.  Appropriate 
supplementation could be a cost effective strategy for reducing hyperglycemia in 
pregnancy, thus enhancing the health of mothers and their children.   
Assumptions 
There were several assumptions in this study.  It was assumed that the participants 
all volunteered for the study, met the selection criteria, were truthful in their responses, 
and followed instructions correctly.  It was also assumed that the participants were 
relatively healthy when the testing was done and were not taking any medications or 
experiencing other conditions which could affect results.  The sample was considered to 
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be an accurate reflection of the population studied (pregnant, nulliparous women in the 
upper Midwest).  The last assumption was that all laboratory testing techniques were 
done properly with reliable and accurate results. 
Summary of Key Points 
1. Vitamin D deficiency is a problem worldwide and affects over 40% of the 
adults in the United States alone.  
2. In the second half of pregnancy, women have increased insulin resistance. 
Insulin resistance is part of the complex process from placental hormones 
which reprograms the maternal physiology to meet the needs of the fetus.  
3. Impaired glucose metabolism is a complication of pregnancy with significant 
short-term and long-term consequences for both women and their offspring. 
4. Impaired glucose metabolism in pregnancy includes insulin resistance and 
impaired pancreatic β-cell function which affects insulin production. 
5. Vitamin D has been shown to influence glucose metabolism in the non-
pregnant population. 
6. Both hypovitaminosis-D and impaired glucose metabolism are common 
conditions, especially for women in the Northern Plains of the United States. 
7. Hypovitaminosis-D occurs during pregnancy for certain groups at risk. 
8. Hypovitaminosis-D may be associated with elevated blood glucose levels in 
pregnancy. 
9. Vitamin D supplementation during pregnancy may improve glucose 
metabolism. 
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10. A gap in knowledge exists regarding the relationship between the serum 
vitamin D levels in pregnancy and blood glucose levels at 24-28 weeks of 
gestation. 
11. Finding a cost effective, easily implemented intervention to improved glucose 
metabolism in pregnancy would contribute to both science and clinical 
practice.    
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CHAPTER II 
REVIEW OF LITERATURE 
Introduction 
This chapter contains a review of the literature related to the relationship between 
vitamin D levels at different times in pregnancy and the blood glucose level in mid-
pregnancy.  In the non-pregnant population, there is growing evidence that vitamin D is 
an important regulator of blood sugar metabolism and influences increased insulin 
secretion (Forouhi et al., 2008; Hirani, 2011) which has generated interest on the 
influence of maternal vitamin D status on blood glucose metabolism in pregnancy.  The 
topics covered in this review include metabolic changes in pregnancy related to glucose 
metabolism, the effects of hyperglycemia during pregnancy on both the woman and her 
offspring, an overview of vitamin D including the effect on glucose metabolism, and the 
influence of vitamin D on glucose metabolism in pregnancy.  The review of literature 
provided the foundation for the research questions for this study.   
Definitions 
The following definitions of terms used in the current study are written below to 
provide clarity: 
Active vitamin D: 1,25(OH)2D; the hormonal form of vitamin D; also known as 
calcitriol.  In this paper, the term calciTRiol will be used. 
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Blood glucose level (BG): amount of glucose in the blood measured in mg/dl.  In 
this study, the BG was obtained at 24-28 weeks gestation after ingestion of a 50 gram 
glucose beverage at a GDM screening.  Sometimes commonly called blood sugar. 
Elevated BG at GDM screening:  >140 mg/dl one hour after ingestion of 50 gram 
glucose beverage at 24-28 weeks of gestation (Hartling et al., 2012; Hollander, Paarlberg 
& Huisjes, 2007) 
Gestational diabetes mellitus (GDM): carbohydrate intolerance of variable 
severity with onset or first recognition during pregnancy.  A blood glucose level > 140 
mg/dl at the GDM screening test or a diagnosis of GDM in the medical record 
abstraction.  
Glucose intolerance: hyperglycemia secondary to insulin resistance. 
Hypovitaminosis-D:  insufficient or deficient vitamin D level indicated by a blood 
serum calcidiol which is less than adequate for this population.  In this paper, vitamin D 
is being studied for a non-skeletal influence and therefore level has been set at < 75 
nmol/L.  See the review of the literature for further details.   
Hyperglycemia: an abnormally high concentration of glucose in the blood.  For 
the purposes of this paper, this means a blood glucose level > 140 mg/dl at the GDM 
screening test 
Insulin resistance: physiologic condition in which insulin is produced by the 
pancreas but the cells fail to respond adequately which results in the need for the 
pancreas to produce higher amounts of insulin to maintain glucose homeostasis  
IU: International Unit   
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Serum vitamin D: 25(OH)D level in the blood serum, also known as calcidiol or 
25-hydroxyvitamin D.  It is the stored form of vitamin D that circulates in the body.  
Serum calcidiol is used to measure vitamin D levels.  See methods for data collection 
information.  In this paper, the term calciDiol will be used.   
Vitamin D: generic descriptor for all steroids exhibiting the biologic activity of 
ergocalciferol or cholecalciferol.  They promote the proper use of calcium and 
phosphorus, thereby favoring proper bone and tooth formation.  The physiological 
processes which begins with vitamin D intake from synthesis or consumption and 
becomes the active, hormonal form is very complex and is discussed in the review of 
literature. 
Vitamin D2: ergocalciferol; the activated ergosterol, the vitamin D of plant origin; 
sterol occurring naturally in fungi and some fish oils or synthesized from ergosterol; it 
arises from ultraviolet irradiation of ergosterol, and similar to cholecalciferol in activity 
and metabolism.  It is added to foods such as milk as a dietary source of vitamin D or 
used as a supplement. 
Vitamin D3: cholecalciferol; vitamin D of animal origin found in the skin of 
animals exposed to sunlight; can also be manufactured as a supplement 
VitD-early: calcidiol level drawn at 10-14 weeks gestation; also VitD.early 
VitD-mid: calcidiol level drawn at 22-26 weeks gestation; also VitD.mid 
VitD-late: calcidiol level drawn at 32-26 weeks gestation; also VitD.early 
Weeks of gestation, weeks gestation: designation of time frame in pregnancy 
measured in completed weeks 
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Adaptations to Glucose Metabolism in Pregnancy 
Pregnancy is a time of significant alterations and increasing metabolic demands 
for the woman (Torgersen & Curran, 2006) including changes in glucose metabolism 
(Cunningham et al., 2013; Evensen, 2012).  In pregnancy, there are progressive changes 
in glucose metabolism which result in a decrease in fasting blood glucose (Gabbe et al., 
2012, p. 889), sustained postprandial elevation, and hyperinsulinemia (Cunningham et al., 
2013).  In the first trimester, this is likely due to the increase in plasma volume (Gabbe et 
al., 2012, p. 889) which begins at six weeks and continues through the second trimester 
(Torgersen & Curran, 2006) while in later pregnancy, this is most likely as a result of the 
glucose needs of the fetus and placenta.   
The placenta obtains glucose primarily through facilitated diffusion and the main 
glucose transporter in the placenta is GLUT1 (Brett, Ferraro, Holick & Adamo, 2015; 
Brett, Ferraro, Yockell-Lelievre, Gruslin, and Adamo, 2014; Day, Cleal, Lofthouse, 
Hanson & Lewis, 2013).  This results in non-insulin mediated glucose utilization by both 
the fetus and the placenta which gradually increases with advancing gestation, which 
further contributes to the changing glucose metabolism in pregnancy.  There is an 
increased potential for the transport of glucose to the fetus correlated to maternal sugar 
intake (Brett et al., 2015).  Simultaneously as the gestation advances, women develop 
decreasing peripheral insulin sensitivity, a gradual decrease in fasting blood glucose 
levels, and a progressive increase in the postprandial blood sugar levels (Gabbe et al., 
2012, p. 888-890).  The availability of nutrients in the maternal circulation influences 
nutrient transport to the fetus by the placenta (Brett et al., 2015).  The placenta is 
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considered to be a dynamic, responsive organ in the transport of glucose and other 
nutrients to the fetus. 
 
 
Figure 1.  Glucose transport in placenta to fetus. 
Changing Insulin Metabolism 
Early pregnancy is characterized by alterations in maternal metabolism to provide 
adequate nutrition to the placenta and the fetus.  These metabolic changes are attributed 
to pregnancy-related hormones including human placental lactogen, estrogen, 
progesterone, prolactin, and cortisol (Evenson, 2012; Maghbooli et al., 2008).  Glucose 
metabolism is changed by an increase in insulin resistance and reduced uptake of glucose 
by maternal tissues which results in higher postprandial blood glucose levels (Maghbooli 
et al., 2008).  Simultaneously, the placenta utilizes glucose which then results in lower 
fasting blood glucose levels (Gabbay-Benziv & Baschat, 2015).  As the pregnancy 
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progresses the insulin resistance increases to facilitate glucose delivery to the fetus 
(Evensen, 2012).   
Factors Contributing Insulin Resistance in Pregnancy 
Normally, this state of increased insulin resistance in the second half of pregnancy 
is similar to the underlying pathophysiology of type 2 diabetes (Evensen, 2012; Jelsma et 
al., 2013).  In both conditions, the increasing insulin resistance along with an inadequate 
response of the β-cells to produce the amount of insulin needed leads to hyperglycemia 
(Gabbe et al., 2012, p. 892).  Although not yet fully understood, insulin receptors found 
in the placenta undergo developmental changes as the pregnancy progresses which 
strongly suggest a shift from maternal control to fetal control of insulin dependent 
functions (Desoye & Hauguel-de Mouzon, 2007).  In the microvillus trees of the 
placenta, there is diffusion of glucose from the higher concentration in the maternal blood 
supply to the lower concentration on the fetal side of the placenta.  The glucose supplied 
to the developing fetus is dependent upon the concentration gradient between the mother 
and baby.  The main glucose transporter in this process is GLUT1 which provides a 
binding site at the basal membrane and faster, facilitated diffusion.  The placenta also 
utilizes a considerable amount of glucose which buffers the glucose fluctuations to the 
fetus (Barta & Drugan, 2010). 
Maternal Hyperglycemia in Pregnancy 
Hyperglycemia occurs in pregnancy when the body is unable to respond to the 
physiologic changes by increasing insulin production to meet the changes in glucose 
metabolism (Coustan, 2013).  Emerging research demonstrates that maternal 
hyperglycemia is clinically important, even when less severe than the level associated 
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with a diagnosis of gestational diabetes mellitus (The HAPO Study Cooperative Research 
Group, 2008).  Glucose metabolism is on a continuum (Salzer, Tenenbaum-Gavish & 
Hod, 2015) with a linear association between maternal blood glucose levels in pregnancy 
and unfavorable perinatal outcomes (Tieu, McPhee, Crowther & Middleton, 2014).  A 
fetus is more sensitive to hyperglycemia than to hypoglycemia when it comes to 
well-being (Evensen, 2012).  Studies such as the HAPO study demonstrate that adverse 
outcomes for mother and baby can be a result of hyperglycemia in pregnancy (Coustan 
Lowe, Metzger, & Dyer, 2010).  However, the threshold for maternal blood glucose 
levels which predicts adverse perinatal outcomes has not yet been found (Tieu, McPhee, 
Crowther, & Middleton, 2014).    
The HAPO study examined any association between blood glucose levels and 
adverse pregnancy outcomes (Coustan et al., 2010).  Over 25,000 women were involved 
in the study and various research teams analyzed the data.  Fasting blood sugar (FBS) 
levels and/or oral glucose tolerance test (OGTT) results were used and the study was 
powered for the primary outcomes of macrosomia, neonatal hypoglycemia, cesarean 
delivery, and hyperinsulinemia (Coustan et al., 2010). The secondary outcomes in the 
HAPO study included shoulder dystocia, preterm birth, birth injury, neonatal intensive 
care admission, pre-eclampsia, and hyperbilirubinemia (Coustan et al., 2008). Both 
obesity and gestational diabetes mellitus pose a greater risk for adverse outcomes in 
pregnancy with a combination of both leading to even greater risk for these unfavorable 
consequences (Catalano et al., 2012).   
Maternal blood glucose was considered a continuous variable for the analysis 
(Coustan et al., 2010).  Maternal hyperglycemia at levels less severe than GDM causes 
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fetal hyperinsulinemia and fetal overgrowth (The HAPO Study, 2009).  The adverse 
effects of maternal hyperglycemia on the infant can result in the need for more medical 
interventions at birth including costly admissions to the neonatal intensive care unit 
(Landon et al., 2012; Desoye & Hauguel-de Mouzon, 2007; Vambergue & Fajardy, 
2011).  The HAPO Study (2009) concluded that there is a need to look at treating 
hyperglycemia in pregnancy, considering the findings of adverse outcomes. 
When the fetus is exposed to ongoing hyperglycemia in utero, there is an 
increased risk for the adult onset of disease (Lapillone, 2009; Lehnen et al., 2013; Tieu et 
al., 2014; Veeraswarmy et al., 2012).  Prolonged maternal hyperglycemia during 
pregnancy can lead to health problems in later life for the offspring including childhood 
obesity, development of metabolic syndrome, and type 2 diabetes in young adulthood 
(Tieu et al., 2014; Veeraswamy, Vijayan, Guptz, & Kapur, 2012).  Fetal overnutrition at 
periods critical in fetal development (Javaid et al., 2006) can lead to metabolic conditions 
such as obesity, glucose intolerance, or type 2 diabetes.  These studies demonstrates how 
such conditions can originate from the effects of the intrauterine environment on the 
developing fetus (Hunt & Schuller, 2007; Lehnen et al., 2013; Veeraswarmy et al., 2012).  
The known physiologic changes in pregnancy which can results in prolonged 
hyperglycemia have resulted in routine screening protocols to diagnose gestational 
diabetes mellitus (GDM) (Tieu et al., 2014).  The protocols were implemented because 
GDM can occur among pregnant women traditionally considered to be low risk for 
complications (Holmes et al., 2009; Lehnen et al., 2013; Macones, 2012; Poel et al., 
2012).  Gestational diabetes mellitus (GDM) is briefly defined as carbohydrate 
intolerance that is first recognized during pregnancy (Asemi, Hashemi, Karamali, 
23 
Samimi, & Esmaillzadeh, 2013).  Left uncontrolled, GDM can result in hyperglycemia 
during pregnancy with the resulting adverse effects.  Infants of women with GDM have 
increased perinatal morbidity including macrosomia, hypoglycemia, respiratory distress 
syndrome, and jaundice (Coustan, 2013).   
Vitamin D Metabolism  
Vitamin D is recognized today as a prohormone (Institute of Medicine, 2011) and 
is a unique nutrient because it is obtained through cutaneous synthesis from ultraviolet 
rays from direct sunlight (from UVB radiation at 290-320 nm) on exposed skin (Brannon 
& Picciano, 2011) and can also be obtained through certain foods or dietary supplements 
(Specker, 2004; Tomedi, Simhan, & Bodnar, 2013).  Vitamin D2 (ergocalciferol) is 
naturally found in a few foods or is manmade (IOM, 2011; Specker, 2004).  Vitamin D3 
(cholecalciferol) is produced in human skin from 7-dehydrocholesterol (7-DHC) or 
ingested through animal based foods (IOM, 2011).  Both forms, D2 and D3, are 
commercially manufactured for supplements (IOM, 2011). 
Both forms of vitamin D (D2 and D3) are biologically inactive and must undergo 
two hydroxylations before becoming biologically active (Brannon & Picciano, 2011; 
Holick & Chen, 2008).   The first hydroxylation occurs in the liver where an enzyme, 25-
hydroxylase (CYP2R1), converts vitamin D into 25-hydroxyvitamin D which is also 
referred to as 25(OH)D or calcidiol (Brannon & Picciano, 2011; Holick & Chen, 2008; 
IOM, 2011).  Calcidiol is the major form of vitamin D in the circulation and is bound to a 
carrier protein, vitamin D binding protein (known as VDP) in the plasma (IOM, 2011).  
Calcidiol has a half-life of 15 days (Jones, 2008) and is the best indicator of serum 
vitamin D status (Holick & Chen, 2008; Olmos-Ortiz, Durand-Carbajal, & Diaz, 2015) 
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because it reflects the cumulative effect of sunlight, diet, and supplements in the 
circulation (Kovacs, 2013).  Although calcidiol has a sufficient half-life to most 
accurately reflect the vitamin D from all sources (Brannon, 2012), it does not accurately 
reflect the stores within the body tissues (National Institutes of Health, n.d.).   
Calcidiol is changed into calcitriol (1,25(OH)2D) through the second 
hydroxylation in the maternal kidneys and, in lesser amounts by the fetal kidneys, the 
placenta, the decidua, and diverse tissues (Barrett & McElduff, 2010; Kovacs, 2013).  An 
enzyme in the kidneys, 1α-hydroxylase (CYP27B1), converts the calcidiol into the 
physiologically active form, 1,25 dihydroxyvitamin D, which is also referred to as 
1,25(OH)2D or calcitriol (Holick & Chen, 2008; IOM, 2011).  Calcitriol synthesis in the 
kidney is tightly controlled with up-regulation by the parathyroid hormone and down-
regulation by fibroblast-like growth factor.  Some extra-renal tissues contain 1α-
hydroxylase, but it is yet unknown how this contributes to calcitriol production (IOM, 
2011).  Calcitriol acts through the vitamin D receptors (VDR) to produce the favorable 
biological effects (Lapillonne, 2009).  Calcitriol which has a half-life of 15 hours (Jones, 
2008) yet levels of calcitriol typically do not decrease until there is severe vitamin D 
deficiency (NIH, n.d.).  Calcitriol has a significant physiological influence on essentially 
every tissue and cell in the human body (Holick, 2005; Lips, 2006; McCullough, 2007; 
Pittas & Dawson-Hughes, 2010) and may even have a protective effect against many 
diseases (Lapillone, 2009).  
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Figure 2.  Vitamin D metabolism. 
 
Hypovitaminosis-D 
Concerns exist about the high prevalence of hypovitaminosis-D in pregnancy 
(Bodnar et al., 2007; Brannon & Picciano, 2011) which exists in almost every population 
studied (Dror, King, Durand, & Allen, 2011).  Today, hypovitaminosis D can be 
attributed to lifestyle changes which result in less sunlight exposure on bare skin from the 
use of sunscreen, fewer hours spent outside, and clothing choices due to culture or 
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climate (Dawodu & Akinbi, 2013; Wagner et al., 2013; Wang et al., 2013).  The reduced 
amount and seasonal nature of sunlight exposure, smoking, and obesity have all been 
associated decreased vitamin D levels (Andersen et al., 2013; Evensen, 2012).  Vitamin 
D synthesis from direct sunlight is reduced as melanin increases in the skin or due to 
changes in UV radiation from sunlight when people live at higher latitudes (Holick & 
Chen, 2008; Schroth, Lavelle, & Moffat, 2005).  The individual’s metabolism of vitamin 
D can be influenced by factors which include renal function, liver function, ethnicity, and 
genetic effects (Collins-Fulea et al., 2012; Holmes et al., 2009; Prentice, 2008; Wicherts 
et al., 2011).   
Prevalence of Hypovitaminosis D 
Vitamin D deficiency is a problem worldwide and may affect as much as 42% of 
the adults in the United States (Forrest & Stuhledreher, 2011; Ginde, Sullivan, Mansbach, 
& Camargo, 2010; Hanley & Davison, 2005; Holick, 2008; Vieth, 2006).  Some 
researchers have described hypovitaminosis D as reaching pandemic levels because it is 
prevalent in Asia, China, the Scandinavian countries, the United Kingdom, Canada, the 
northern United States, and in African Americans (Holick & Chen, 2008; Glerup et al., 
2000; Hanley & Davison, 2005; Wang et al., 2012).  The prevalence of hypovitaminosis-
D is approximately 5-29% of pregnant women in the United States (Brannon & Picciano, 
2011).   
The Institute of Medicine (IOM) developed the dietary reference intakes (DRI) 
through a joint effort between the United States and Canadian governments (Aloia, 
2011).  The DRI of vitamin D was recently increased from 400 IU to 600 IU daily for 
adults, including pregnant women (Aloia, 2011).  Many researchers believe this is still 
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not adequate and argue that the DRI should be 800-2000 IU (Ginde et al., 2010; Hanley 
& Davison, 2005; Heaney, 2005).  The most effective method to achieve an increase in 
vitamin D is through dietary supplements (Hanley & Davison, 2005; Heaney, 2005; 
Thorne-Lyman & Fawzi, 2012).  The IOM recommendations state that vitamin D toxicity 
is unlikely to occur until doses exceed 10,000 IU/day (IOM, 2011).  However, vitamin D 
intake and serum vitamin D levels do not have a linear relationship (IOM, 2011) so the 
best way to determine vitamin D status is through a serum calcidiol level (Holick & 
Chen, 2008; Olmos-Ortiz et al., 2015).   
Vitamin D in Pregnant Women 
Unless there is an increase in intake of vitamin D from diet, supplements, or from 
synthesis in the skin, serum calcidiol levels don’t change during pregnancy (Gabbe et al., 
2012, p. 59).  During pregnancy, calcitriol progressively increases by 50-100% in the 
second trimester and to twice the pre-pregnancy level in the third trimester, most likely 
due to production by the increasing placental mass (Cho, Hong, Oh, & Kim, 2013).  This 
change occurs from an increase in production of calcitriol from calcidiol by the maternal 
kidneys as well as conversion of calcidiol into calcitriol by the placenta, the decidua and 
the fetal kidneys (Barrett & McElduff, 2010; Kovacs, 2013).  The increase in maternal 
calcitriol starts in early pregnancy but the increase in free calcitriol does not occur until 
late pregnancy.  This occurs because the maternal kidneys upregulate the expression of 
the enzyme, CYP27B1, which increases the production of calcitriol.  The fetal kidneys, 
the placenta, and the maternal decidua are also sources of CYP27B1 expression but only 
results in a small amount of calcitriol.  Their contribution is not enough to account the 
increase of calcitriol in maternal circulation in pregnancy (Kovacs, 2013).  
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Hypovitaminosis-D in Healthy Pregnant Women 
 Hypovitaminosis-D was detected in women of childbearing age who are 
considered healthy and at low risk for pregnancy complications (Holmes et al., 2009).  
Although vitamin D levels were significantly lower in the pregnant women in their study, 
Holmes et al. (2009) reported hypovitaminosis-D in the non-pregnant women from the 
control group in their study demonstrating that hypovitaminosis-D is prevalent in all 
women who are of childbearing age.  Specific groups of pregnant women such as those 
who are veiled or have deeply pigmented skin have a high prevalence of 
hypovitaminosis-D (Bodnar et al., 2007; Dawodu & Akinbi, 2013; Marwaha et al., 2011; 
Wagner et al., 2013; Wang et al., 2013).   
The Endocrine Society and the Institute of Medicine (IOM) have differing 
recommendations on the amount of vitamin D supplementation required in pregnancy.  
The IOM recommends 600 IU/day of vitamin D for all adults with no change for women 
during pregnancy (IOM, 2011). The Endocrine Society recommends 600 IU of vitamin D 
daily for pregnant women between 14-18 years of age and 1500-2000 IU daily for 
pregnant women ages 19-50 years of age (Holick et al., 2011).  If needed, The Endocrine 
Society recommends supplementations of 1,500-2,000 IU of vitamin D daily to reach a 
target level of serum calcidiol of 75 nmol/mL (Hollis et al., 2011).  However, Kovacs 
(2013) reports that women do not need more vitamin D during pregnancy as compared to 
the non-pregnant state because maternal calcitriol normally increases in pregnancy due to 
increased expression of CYP27B1 in the maternal kidneys.  Kovacs (2013) states that 
there is inconsistent data for any non-skeletal benefits from vitamin D and does not 
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recommend additional vitamin D during pregnancy until clinical trials prove there is a 
need.   
Hypovitaminosis-D is prevalent in many women during pregnancy (Aslam et al., 
2012; Hollis et al., 2011; Maghbooli et al., 2008) underscoring the importance of 
investigating the effect of vitamin D on health outcomes related to this population 
(Barrett & McElduff, 2010; Ginde et al., 2010; Holmes et al., 2009; Mulligan, Felton, 
Riek, & Bernal-Mizrachi, 2010).  Universal screening is not recommended at this time, 
but targeted screening may be indicated for pregnant women in some at-risk groups 
(Collins-Fulea et al., 2012).  Serum levels of calcidiol increase in proportion to intake 
through both sunlight exposure and oral intake from supplements or food (IOM, 2011).  
The dose-response varies in individuals based on the degree and duration of 
supplementation and the baseline calcidiol levels (IOM, 2011). 
Hypovitaminosis-D and Glucose Metabolism 
The National Health and Nutrition Examination Survey (HANES) showed an 
inverse association between diabetic risk and serum calcidiol for some ethnic groups, but 
not for all (Scragg, Sowers, & Bell, 2004).  There is evidence that vitamin D has an effect 
on glucose metabolism (Chiu et al., 2004;  Forouhi et al., 2012; Moreira & Hamadeh, 
2010; Holick, 2005; Pittas & Dawson-Hughes, 2010; Palomer et al., 2008) but the 
physiological reason is not fully understood.  It is unknown if vitamin D affects insulin 
sensitivity, β-cell function in the pancreas, or a combination of these (Clifton-Bligh et al., 
2008).  Several researchers have shown that vitamin D affects β-cell function in the 
pancreas, insulin secretion and insulin resistance which subsequently affects blood 
glucose metabolism (Alfonso et al., 2009; Kayaniyil et al., 2011; Zhao, Ford & Li, 2010).  
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Others have reported an inverse association between hypovitaminosis-D and insulin 
resistance, plasma glucose levels, and diabetes (Chiu et al., 2004; Ford, Ajani, McGuire 
& Lui, 2005; Forouhi et al., 2008; George, Person & Witham, 2012; Heaney, 2005; 
Kayaniyil et al., 2010;  Moreira & Hamadeh, 2010; Patra et al., 2012; Pittas et al., 2010).  
McLeod et al. (2012) reported that vitamin D may affect glucose metabolism through 
influence of β-cell function.  In summary, there is evidence that vitamin D influences 
glucose metabolism through insulin production or sensitivity, though the precise details 
have yet to be determined. 
Insulin resistance contributes to hyperglycemia and impaired glucose tolerance 
(IGT) which is then linked to the development of diabetes mellitus (Muscogiuri et al., 
2011; Song & Mason, 2010).  A study in healthy young adults with normal glucose 
metabolism demonstrated an association between hypovitaminosis-D and decreased 
insulin secretion which was normalized after vitamin D supplementation (Jorde & 
Figenschau, 2009).  Another study demonstrated that vitamin D3 supplementation 
improved postprandial sensitivity in a targeted group (Nagpal, Pande, & Bharita, 2009).  
Some researchers have suggested that higher levels of vitamin D might have a protective 
effect against development of both type 2 and type 1 diabetes (Jorde & Figenschau, 2009; 
Harris, 2005).  If such a correlation between hypovitaminosis-D and hyperglycemia 
exists, it creates the potential to study vitamin D supplementation as a method for 
improving glucose metabolism during pregnancy (Tomedi, Simhan & Bodnar, 2013).   
Insulin Resistance and Hypovitaminosis-D in Pregnancy 
The normal insulin resistance of pregnancy may be compounded by the metabolic 
consequences of hypovitaminosis-D which itself can contribute to insulin resistance and 
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impaired glucose metabolism.  A limited number of large studies have supported the 
premise that maternal hypovitaminosis D during pregnancy is linked to insulin resistance, 
elevated fasting blood glucose levels, or GDM (Burris et al., 2013; Jensen et al., 2013; 
Maghbooli et al., 2008).  Retrospective studies examining the relationship between a 
diagnosis of gestational diabetes mellitus (GDM) and serum calcidiol levels failed to find 
an association between hypovitaminosis-D and a diagnosis of GDM, yet the researchers 
reported that they did find an association between hypovitaminosis-D and elevated blood 
glucose levels (Farrant et al., 2009; Lau et al., 2011).  These discrepancies are evidence 
that there continues to be a gap in knowledge on the influence of hypovitaminosis-D on 
glucose metabolism in pregnancy.  Since pregnancy results in progressive physiological 
changes, the relationship between calcidiol and blood glucose in early, mid, and late 
pregnancy will be discussed. 
Hypovitaminosis-D in Early Pregnancy 
Scientists examining vitamin D levels in the first trimester (early pregnancy) did 
not find an association between serum vitamin D and GDM.  Baker et al., 2012; 
Fernandez-Alonso et al., 2012; Makgoba et al., 2011; Tomedi et al., 2013; Zhang et al., 
2008).  Baker et al. (2012) investigated the relationship of first trimester vitamin D 
deficiency and the risk of GDM based on the premise that hypovitaminosis-D might be 
related to dysfunction of pancreatic β-cells leading to impaired glucose metabolism.  The 
researchers used a nested case-control approach with 180 women in their sample.  They 
used stored serum collected in the first trimester for calcidiol levels and blood glucose 
levels from the GDM screening at 24-28 weeks gestation.  They were unable to prove 
their hypothesis that first trimester hypovitaminosis-D was related to higher levels of 
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GDM because so few of the participants in their study had hypovitaminosis-D (Baker et 
al., 2012).  
Fernandez-Alonso et al. (2012) examined pregnancy outcomes and first trimester 
(early pregnancy) vitamin D levels for 466 women in a cross-sectional study in Spain.  
Participants had a serum blood drawn between 11-14 weeks gestation at their first 
prenatal visit then were followed to the end of pregnancy.  Seasonal variations in vitamin 
D levels were found based on the first trimester being in the spring/summer compared to 
the fall/winter and this seasonal variation continued into the second trimester.  They also 
found a progressive and significant decrease in vitamin D levels from the first to the third 
trimester which was independent of season of the year.  However, perinatal outcomes did 
not vary based on the calcidiol levels in the first trimester (Fernandez-Alonso et al., 
2012).   
Makgoba et al. (2011) looked for an association between serum vitamin D in the 
first trimester and development of GDM in a prospective, case-controlled study of 248 
women.  Blood samples collected in the first trimester were used from a multiethnic 
group consisting of 90 women who developed GDM and a control group of 158 women.  
The women in the study were receiving care in inner-city London.  There was a negative 
correlation between the calcidiol level at the initial prenatal visit in the first trimester and 
the glucose level obtained in mid-pregnancy at a two hour glucose test.  However, there 
was not a statistically significant difference between the calcidiol levels in the group of 
women who developed GDM when compared to the group who did not develop GDM.  
Univariate analysis showed a positive association between calcidiol levels and maternal 
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age and a negative association between calcidiol levels and the first trimester BMI 
(Makgoba et al., 2011).   
The Study of Nutrition and Pregnancy (SNAP) data was used by Tomedi et al. 
(2013) to investigate the association between the calcidiol levels in early-pregnancy (< 16 
weeks gestation) and the blood glucose levels collected at 24-28 weeks gestation which 
was through a routine glucose screening test.  They defined hypovitaminosis-D as a 
serum calcidiol level < 50 nmol/L.  There were 429 women in their sample.  They found 
that 67% of the women had hypovitaminosis-D and 11% of the women had 
hyperglycemia.  They did not find a difference in the calcidiol and glucose levels when 
using the Pearson chi-squared or the Students’-test.  They then looked at calcidiol as a 
continuous variable with logistic and multivariate linear regression models to examine 
the association between the maternal calcidiol levels and blood glucose levels or 
hyperglycemia. Smoking status was included in the data set.  Among the smokers, 
calcidiol levels in the first trimester were lower for those with hyperglycemia at mid-
pregnancy.  This association was not found for the non-smokers.  In their analysis, they 
considered that this may be due to the attributes of their cohort (young, nulliparous, with 
low incidence of GDM) or that smoking may concurrently reduce vitamin D levels and 
increase blood glucose concentrations due to oxidative stress.  They reported this may 
have resulted in the association between hypovitaminosis-D and hyperglycemia in the 
participants who smoked. 
Zhang et al. (2008) used a subset of the Omega Study to investigate the 
association between serum calcidiol levels in early pregnancy and the risk for GDM.  The 
subset consisted of 57 women with a diagnosis of GDM and 114 women without this 
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diagnosis as controls out of the complete data set had a total of 953 participants.  The 
researchers used the Student’s t test to examine the mean calcidiol levels between the two 
groups.  They reported that the participants with a diagnosis of GDM had a significantly 
lower serum calcidiol concentration than the control group (24.2 ng/ml vs. 30.1 ng/ml, P 
< 0.001) after controlling for maternal age and BMI.  They concluded that 
hypovitaminosis-D in early pregnancy (< 16 weeks gestation) was associated with a 
significantly increased risk for GDM.  The researchers analyzed the characteristics of the 
participants and reported that, in general, the women who developed GDM were older 
and heavier than those who did not develop GDM.  However, they report that even after 
controlling for these variables, the inverse association between early pregnancy calcidiol 
levels and GDM risk remained statistically significant (Zhang et al., 2008). 
The studies described above demonstrate that science has not yet been able to 
determine the nature of the relationship between calcidiol levels and glucose metabolism 
in pregnancy.  Many researchers used the diagnosis of GDM as a measure of 
hyperglycemia from impaired glucose metabolism.  For the purposes of this study, GDM 
will be used as proxy to hyperglycemia in pregnancy. 
Hypovitaminosis-D in Mid Pregnancy 
Some researchers have reported an increased risk for GDM when women have 
hypovitaminosis-D in the second trimester (Burris et al., 2012; Clifton-Bligh et al., 2008; 
Maghbooli et al., 2008; Parlea et al., 2012; Soheilykhah et al., 2012; Yap, Gunton, Munns 
& McLean, 2014).  Burris et al. (2012) concluded that mid pregnancy serum vitamin 
calcidiol levels were inversely associated with the blood glucose level obtained one hour 
after a 50 gram glucose load.  Clifton-Bligh et al. (2008) reasoned if vitamin D 
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influenced insulin sensitivity or release, any effects of hypovitaminosis-D would become 
apparent in later pregnancy when progressive insulin resistance affects glucose 
metabolism.  In their prospective study, they found a non-linear, inverse correlation 
between serum vitamin D levels and fasting glucose but this significance became 
borderline when they included body mass index (BMI) in the analysis (Clifton-Bligh et 
al., 2008).    
Maghbooli et al. (2008) found higher insulin resistance and fasting blood glucose 
levels in a group of pregnant women with hypovitaminosis-D, even after adjusting for the 
confounding variables of age and BMI.  However, they found hypovitaminosis-D in 71% 
of their sample of pregnant women and severe hypovitaminosis-D in 29% of their sample 
when looking at hypovitaminosis-D and insulin resistance.  They reported that 
hyperglycemia during pregnancy was significantly higher in the group with severe 
hypovitaminosis-D (Maghbooli et al., 2008).   
Soheilykhah et al. (2010) found hypovitaminosis-D (serum calcidiol < 50 nmol/L) 
in 83.3% of the participants with GDM and in 71.2% of the controls (matched in age, 
BMI, and gestation).  They report women with increase blood glucose levels at mid 
pregnancy had significantly lower serum calcidiol levels compared with the control 
group.  Furthermore, women with GDM had a 2.66 fold increased risk of having serum 
vitamin calcidiol levels < 37.5 nmol/L (Soheilykhah et al., 2010).  
Yap et al. (2014) report there is an increased risk of gestational diabetes mellitus 
associated with hypovitaminosis-D in pregnancy and postulated that high dose vitamin D 
supplementation for women who had hypovitaminosis-D (defined as serum calcidiol < 80 
IInmol/L) before 20 weeks gestation might decrease this risk.  Participants with 
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hypovitaminosis-D were randomized to receive 5,000 IU of vitamin D daily (high dose) 
or 400 IU daily (low dose) and the mid-pregnancy blood glucose levels obtained from an 
oral glucose tolerance test were compared.  There was no difference in the mean maternal 
glucose levels between the two groups.  However, 8% of the participants in the high dose 
group were diagnosed with GDM compared to 13% in the low dose group, and baseline 
serum calcidiol showed an inverse relationship with the blood glucose levels (Yap et al., 
2014).   
Hypovitaminosis-D in Late Pregnancy 
There are limited studies specifically examining the relationship between 
hypovitaminosis-D and hyperglycemia in pregnancy in late pregnancy. Farrant et al. 
(2009) measured serum calcidiol levels and blood glucose levels at 30 weeks of gestation 
in Mysore women living in India.  They did not find a relationship between serum 
vitamin D levels at 30 weeks of gestation and gestational diabetes mellitus (GDM) but 
they did find a high level of hypovitaminosis-D in their sample.  They reported that, in 
women with hypovitaminosis-D, higher vitamin D levels were associated with lower BG 
levels at the 30 minute interval during an oral glucose tolerance test (Farrant et al., 2009).     
McLeod et al. (2012) report that insulin resistance develops in the second and 
third trimesters of pregnancy and that vitamin D may affect glucose metabolism through 
influence on the β cells of the pancreas.  Lau et al. (2011) examined glycated hemoglobin 
(HgA1c) and serum calcidiol levels in late pregnancy.  They found hypovitaminosis-D in 
41% of their participants and concluded lower serum calcidiol levels was associated with 
impaired glucose metabolism.  They reported an inverse association between the vitamin 
D level and glucose control in late pregnancy or the third trimester (Lau et al., 2011).   
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Cho et al. (2013) investigated the relationship between vitamin D levels drawn at 
the time of birth (late pregnancy) and the blood glucose level drawn at 24-28 weeks 
gestation.  They found that 85% of the women diagnosed with GDM had 
hypovitaminosis-D (calcidiol < 20 ng/mL) and 27.5% of the women with normal 
pregnancy had hypovitaminosis-D.  They concluded that there was an association 
between hypovitaminosis-D and GDM (Cho et al., 2013).   
It is interesting to note that the studies in the third trimester reported an inverse 
association between serum vitamin D levels and blood glucose (Cho et al., 2013; Farrant 
et al., 2009; Lau et al., 2011) even though these studies were methodologically different.  
Cho et al. (2013) investigated serum calcidiol levels just before delivery and found a 
higher incidence of hypovitaminosis-D in the women with GDM.  Farrant et al. (2009) 
found an association between vitamin D levels and BG levels at the 30 minute interval 
during an oral glucose tolerance test, but not an association with the other blood glucose 
levels in the test nor with a diagnosis of GDM.  Lau et al. (2011) looked at serum 
calcidiol levels at the time of a glycated hemoglobin test in the third trimester for women 
with known GDM and found an inverse association between calcidiol levels and 
glycemic control.  
Summary 
Optimal health in pregnancy requires unimpaired glucose metabolism which may 
depend upon adequate levels of biologically active vitamin D.  The GDM screening is a 
single value at one point in time based on a protocol and the criteria for diagnosing GDM 
are not consistent or have been changed periodically over the years (Coustan et al., 2010).   
The pregnancy related problems of GDM are a result of hyperglycemia (Aghajafari et al., 
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2013; Desoye & Hauguel-de Mouzon, 2007; Landon et al., 2012; Vambergue & Fajardy, 
2011).  Researchers and clinicians are just a beginning to understand the impact of 
vitamin D during pregnancy on the health of the mother and the future health of the 
developing fetus (Barker, 2007; Barker & Bagby, 2010; Bergstrom, Blanck & Savendahl, 
2013).  Maternal hypovitaminosis-D is quite possibly a modifiable risk factor which can 
be targeted to improve pregnancy outcomes and even prevent hyperglycemia in 
pregnancy through the simple, cost effective use of vitamin D supplementation (Parlea et 
al., 2012; Poel et al., 2012; Senti, Thiele & Anderson, 2012).  Preventing 
hypovitaminosis-D during pregnancy supports an optimal intrauterine environment which 
may impact the health of future generations (Barker, 2005, 2007; Holt, Coleman, & 
McCance, 2011).   
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CHAPTER III 
METHODS 
Introduction 
Chapter III provides details on the study design, population and sample, and 
sampling procedures.  Discussion includes each of the study variables which are maternal 
age, body mass index (BMI), calcidiol levels at three points during pregnancy, and blood 
glucose in mid-pregnancy.  The data analysis process is discussed.  The chapter ends with 
limitation of the study.   
The purpose of this study was to determine the relationship between calcidiol 
levels collected in early, mid, and late pregnancy and blood glucose levels in mid 
pregnancy in a sample of women in an upper Midwestern region of the United 
States.  Calcidiol influences glucose metabolism in the non-pregnant population (Alfonso 
et al., 2009; Mathieu et al., 2005; Pittas et al., 2006; Tohidi et al., 2013) and this study 
investigated the influence of calcidiol on glucose metabolism in the pregnant 
population.  Identifying the correlation between calcidiol and glucose levels may inform 
the potential mechanism on the effect of calcidiol on glucose metabolism in pregnancy.  
There were three research questions.  1)  Is there a correlation between the calcidiol level 
at 10-14 weeks gestation and the blood glucose (BG) level at 24-28 weeks gestation when 
controlling for the known confounding variables of age and pre-pregnancy body mass 
index (BMI)?  Is there a correlation between calcidiol level at 22-26 weeks gestation and 
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the BG level at 24-28 weeks gestation when controlling for the known confounding 
variables of age and BMI?  3)  Is there a correlation between the calcidiol level at 32-36 
weeks gestation and the BG level at 24-28 weeks gestation when controlling for the 
known confounding variables of age and BMI? 
Research Design 
A quantitative, correlational design was used in a secondary analysis to ask new 
questions of an existing data set. The level of significance was set at p < .05.  This study 
was designed as a secondary analysis of data collected in a prior prospective study.  An 
advantage of this type of study design is the ability to answer new research questions of 
an existing data set (Castle, 2003; Doolan & Froelicher, 2009).  The primary research 
was a prospective study to examine differences in women that did or did not develop 
preeclampsia (Anderson, Ralph, Wright, Linggi, & Ohm, 2013).  The primary study used 
a convenience sample of women recruited from a community located at latitude of 47.96 
degrees north (Anderson et al., 2014).  The design of the parent study determined the 
inclusion and exclusion criteria.  Eligibility criteria included English speaking nulliparous 
women who were at least 18 years of age carrying a singleton pregnancy.  In addition, 
participants needed to be enrolled between 10 and 14 weeks of gestation, received 
prenatal care in the community, and delivered at the local community hospital.  Exclusion 
criteria included woman who were unable to communicate in English, were younger than 
18 years of age, were not nulliparous, pregnant with multiples, or beyond 14 weeks of 
gestation at time of enrollment.  The data set for the secondary analysis only included 
women who were followed through delivery.   
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Demographic data was collected at enrollment between 10-14 weeks gestation.  
Peripheral blood samples through venipuncture were drawn at 10-14 weeks gestation, 
22-26 weeks gestation, and 32-26 weeks gestation.  The data set acquired for the 
secondary analysis included laboratory results and standard measures from the medical 
record collected during prenatal care, including a blood glucose level at 24-28 weeks 
gestation.   The study was presented and refined based on input from stakeholders 
including groups providing prenatal, labor and birth care as well as nursing staff on the 
inpatient unit where the participants gave birth.  
Population and Sample 
This study used a convenience sample of 52 nulliparous pregnant women who 
received prenatal care and delivered in a single healthcare system in an upper Midwestern 
community of the United States.   All of the participants in the study needed to be at least 
18 years of age, nulliparous, enrolled before 14 weeks gestation, and did not have pre-
existing medical conditions.  The participants volunteered by responding to recruitment 
measures and lived in or near the upper Midwestern community.  All of the women in the 
study received usual prenatal care appropriate to their institution and all were followed 
through delivery.  The study sample was compared with the population of the state of 
North Dakota which represents the region and with the population of the United States.  
This was done to determine generalizability of the study findings.   
Sampling Procedures 
Sampling procedures are discussed below.  This begins with how participants 
were recruited for the study, the time points for data collection, and the process of data 
collection.  Protection of human subjects is discussed at the end of this chapter.  
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Recruitment   
Recruitment occurred through advertising using local print media, the internet, a 
local television community bulletin board, and through flyers posted in the clinics which 
provided ambulatory care to pregnant women in the region.  One page 8x10 inch posters 
were created then placed on bulletin boards in the perinatal clinic areas and on public 
access bulletin boards in grocery stores and shopping areas.  In addition, an 
advertisement was placed in a local “shopper-style” free paper and a similar written 
advertisement was run as part of scrolling announcements on a local public information 
television channel.  Individuals who were interested in participating in the study called 
the phone number listed and were screened for eligibility by a research team member.  
Those who met inclusion criteria met with a trained research assistant at the Grand Forks 
Human Nutrition Research Center (GFHNRC) three times during the prenatal period.    
The first meeting with the research assistant was between 10-14 weeks gestation 
at which time the study was reviewed with the participant, informed consent was 
obtained, and a blood sample was obtained through venipuncture.  The participants 
returned two more times to the GFHNRC for subsequent blood samples through 
venipuncture at 22-26 weeks gestation and at 32-36 weeks gestation (Figure 3).  After 
giving birth, medical record abstraction was performed to obtain the height, pre-
pregnancy weight (or weight at first prenatal medical appointment if pre-pregnancy 
weight was unknown), and the blood glucose routinely obtained in mid-pregnancy 
between 24-28 weeks gestation.   
All participants lived in or near the upper Midwestern community.  All of the 
women in the study received usual prenatal care appropriate to their institution.  All were 
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followed through delivery.  Each woman received a $75 incentive, scaled over three data 
collection points, for completing the study.   
 
Figure 3.  Recruitment and collection of data.  
Instrumentation 
The instrumentation used in this study is discussed in detail below.  Included is 
the process used to obtain the serum calcidiol levels and the manner used to obtain the 
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other variables.  Data about race was obtained and recorded at the time of study 
enrollment.  The medical record was used to obtain pre-pregnancy or initial weight, 
height, and blood glucose level in mid-pregnancy.  Information from the medical record 
was transcribed onto a tool with only the study participant number; there was no 
information which could identify the participants.       
Methods for Calcidiol Blood Sampling 
Peripheral blood samples were collected by venipuncture in early pregnancy 
(10-14 weeks gestation), mid-pregnancy (22-26 weeks gestation), and late pregnancy 
(32-36 weeks gestation).  Serum was extracted from the blood samples for analysis of 
serum calcidiol levels.  Samples were collected, processed, and stored by research staff at 
the Grand Forks Human Nutrition Research Center (GFHNRC) for study enrollment and 
for calcidiol levels.  The participants reported to the GFHNRC at times scheduled for 
data collection at each of three time points in gestation.  Using appropriate universal 
precautions, the research staff performed venipuncture to collect the whole blood from 
the participants.  The blood was collected in two red top serum separator vacutainer (B- 
D, Franklin Lakes) blood tubes.  The blood samples were kept at room temperature for 
one hour to allow clotting then centrifuged for 10 minutes at 1,000 rpm at 4 degrees 
centigrade.  Serum was removed from the red top tubes, aliquoted (500 μl), and frozen at 
-80 degrees centigrade for storage until used for analysis of the serum vitamin D levels in 
the parent study. 
Laboratory Analysis for Serum Calcidiol Levels 
Circulating calcidiol levels were analyzed in the parent study using the 
Immunodiagnostic Systems LTD (IDS) 25-Hydroyxy Vitamin D enzyme-immunoassay 
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(EIA) kit for quantitative determination of calcidiol in serum (Appendix D).  Samples, 
controls and calibrators were diluted with biotin labelled 25-OH D.  To perform the 
analysis, 25 μl of serum was placed in a labelled borosilicate glass or polypropylene tube 
then 1 ml of biotin solution (which dissociates the vitamin D from vitamin D binding 
protein) was added and mixed by a thorough vortex for 10 seconds.  A plate with 
microtitre wells coated with sheep 25-OH D antibody was used and each well was filled 
with 200 µL of the diluted sample.  The plate was sealed and incubated for 2 hours at 
room temperature (18-25 degrees centigrade).  The plate was washed three times with a 
specific washing solution (WASHBUF) included in the kit.  Next, an enzyme conjugate 
which selectively binds to the Vitamin D-biotin complex was added to each well and the 
covered plate was again incubated for 30 minutes at room temperature (18-25 degrees C).  
The wash step was repeated using the WASHBUF (as above), then a chromogenic 
substrate was added to the samples then the reactions was stopped by the addition of a 
hydrochloric acid solution.  Within 30 minutes, a microtitre plate reader is used to 
measure the absorbance of the stopped reactions in each well with the color intensity 
inversely proportional to the 25-OH D concentration.      
Laboratory Analysis of Blood Glucose 
 The blood glucose level was drawn during usual prenatal care at 24-28 weeks 
gestation as part of screening for gestational diabetes mellitus.  Women ingested a 
beverage containing 50 grams of glucose, the time was noted, and a blood glucose levels 
was drawn in one hour per venipuncture by clinic staff.  The blood glucose testing was 
analyzed in the clinic laboratory using standard operating procedures and the results were 
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entered into the medical record.  The blood glucose levels used in this study were 
obtained from the medical record abstraction.  
 The blood sample is placed in either a green top or an SST tube.  A label is placed 
lengthwise on the tube with bar codes which contain the patient identifiers and the 
laboratory test ordered.  The tube is placed in a Megafuge 10 and spun at 32 revolutions 
per minute for 10 minutes to separate the plasma and the red blood cells.  The rubber 
stopper is then removed from the tube, the tube is placed in a sample carrier, and the 
sample carrier is placed in the appropriated bay of the Architect ci 8200.  The machine 
reads the bar code and automatically runs the remainder of the test then prints out results 
for interpretation. The lab protocols include calibration of the machine every 720 days 
and weekly quality control testing (personal communication, Sheila Piper, 10-6-2015). 
Data Collection Procedures 
The participants reported to the Grand Forks Human Nutrition and Research 
Center at points for data collection.  The first collection point was between 10-14 weeks 
gestation and included an overview of the study, informed consent, and venipuncture for 
collection of blood for subsequent vitamin D analysis.  Venipuncture was repeated at 
second and third collection points which were at 22-26 and   32-36 weeks gestation.  
Each blood sample totaled 45 milliliters (three tablespoons) placed into two red top blood 
collection tubes for subsequent serum extraction.  Serum calcidiol levels were obtained 
from the serum blood draws at the GFHNRC at the three data collection points—early 
pregnancy, mid-pregnancy, and late pregnancy.  More specifically, the data collection 
points were at 10-14 weeks gestation (VitD-early), 22-26 weeks gestation (VitD-mid), 
and 32-26 weeks gestation (VitD-late). 
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After birth, medical record abstraction was conducted with data recorded using a 
unique identification unrelated to personal participant information.  The data from the 
medical record included maternal age at delivery, body mass index (BMI), serum blood 
glucose level at 24-28 weeks of gestation.  BMI was calculated using the height and the 
pre-pregnancy weight or the first weight obtained if the pre-pregnancy weight was not 
available.    Descriptive statistics were used to describe the study population.  
Table 1.  Description of Variables and Measurements. 
Variable Data Source or Measurement 
  
Demographics Intake information; medical record 
 
Maternal Age Medical record; age in years at delivery 
 
Body Mass Index (BMI)—weight 
in kilograms (kg); height in 
meters (m) 
 
Medical record; BMI = kg/m2
VitD-early Serum vitamin D level (calcidiol) in nmol/L; 
collected at 10-14 weeks gestation at GFHNRC 
 
VitD-mid Serum vitamin D level (calcidiol) in nmol/L; 
collected at 10-14 weeks gestation at GFHNRC 
 
VitD-late Serum vitamin D level (calcidiol) in nmol/L; 
collected at 10-14 weeks gestation at GFHNRC 
 
Blood Glucose (BG) Blood glucose in mg/dl; collected by clinic lab at 
24-28 weeks of gestation 
 
 
Data Analysis 
The research questions are listed below as a reference for the discussion on data 
analysis.  This is followed by a description of the data set and specific variables.  Finally, 
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the statistical tests used in the analysis are described in detail.  The level of significance 
was set at p < .05 and the measure of variation was standard deviation using the formula: 
. 
Research Questions 
1. Is there a correlation between the calcidiol level at 10-14 weeks gestation and 
the blood glucose (BG) level at 24-28 weeks gestation when controlling for the known 
confounding variables of age and pre-pregnancy BMI? 
2. Is there a correlation between calcidiol level at 22-26 weeks gestation and the 
BG level at 24-28 weeks gestation when controlling for the known confounding variables 
of age and BMI? 
3. Is there a correlation between the calcidiol level at 32-36 weeks gestation and 
the BG level at 24-28 weeks gestation when controlling for the known confounding 
variables of age and BMI? 
Data Set 
Data from a total of 52 participants were analyzed to test for a correlation between 
serum calcidiol levels at three points in pregnancy and the blood glucose (BG) level at 
mid-pregnancy.  The de-identified data used in this secondary analysis was obtained in a 
SAS file, transcribed onto an Excel spreadsheet, verified with the original data to ensure 
accuracy, and examined for anomalies and outliers.  The data set was then loaded into a 
file in the Statistical Package for Social Sciences (SPSS) version 22 (IBM).  These data 
included serum calcidiol levels in nmol/L at 10-14 weeks gestation (VitD-early), serum 
calcidiol levels in nmol/L at 22-26 weeks gestation (VitD-mid), serum calcidiol levels in 
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nmol/L at 32-36 weeks gestation (VitD-late); blood glucose (BG) at 24-28 weeks 
gestation; and height and weight which were used to calculate BMI and age.   
The numeric value for the BMI was used as a continuous variable in the 
calculations.  Age was a numeric, continuous variable.  The numeric value for the serum 
calcidiol level was used as a continuous variable in the multiple regression analysis and 
as a categorical variable (inadequate or adequate calcidiol level) for the t-test.  The 
numeric value for the blood glucose (BG) level was used as a continuous variable in the 
statistical analysis 
Descriptive Data  
The race was obtained for the sample, the population (North Dakota), and the 
nation (United States).  In order to determine if the sample was representative of the 
region and the nation, analysis of variance (ANOVA) was performed which tested the 
differences between the observed and expected proportions.  The results provided a basis 
for generalizability of findings.  This is discussed in greater detail in subsequent chapters. 
Multiple Regression Analysis 
Statistical analysis was performed using SPSS.  A multiple regression analysis 
was utilized to determine if there was a correlation between the independent variables of 
VitD-early, VitD-mid, VitD-late and the dependent variable, BG.  As discussed in 
Chapters I and II, maternal age at delivery and BMI were known confounding variables.  
To control for these confounding variables, BMI and age were also included as 
independent variables in the multiple regression.   
 A regression analysis was the preferred statistical test to look for an association 
because all of the variables were continuous in the data set used in this analysis.  Data for 
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each variable were checked for normality and to verify that the assumptions of the 
statistical procedures were met.  Assumptions for linear regression are linearity and 
additivity, statistical independence, homoscedasticity (constant variance) and normality, 
and these assumptions were met for the data set. A multiple linear regression was chosen 
because there was more than one independent variable; a simple linear regression would 
be used with a single independent and a single dependent variable.   
The working hypothesis for this study was that an inverse relationship would exist 
between serum calcidiol levels during pregnancy and the mid pregnancy blood glucose 
levels.  This hypothesis aligned with the work of other researchers, more specifically that 
of Maghbooli et al. (2008), Soheilykhah, Mojibian, Rashidi, Rahimi-Saghand and Jafari 
(2010), and Zhang et al. (2008).  A one-tailed test was chosen to test for an inverse 
relationship between serum calcidiol levels (VitD-early, VitD-mid, and VitD-late) and 
the BG levels in mid-pregnancy.  When interpreting results, a perfect correlation would 
have been indicated by 1.00; no correlation would have been indicated by 0.00.   
Independent Samples t-test 
The data was coded into categories of inadequate serum calcidiol levels (presence 
of hypovitaminosis-D) and adequate serum calcidiol levels.  This divided the sample into 
two groups (inadequate and adequate serum calcidiol levels).  An independent sample t-
test was used to compare means between the two groups and the BG at each of the time 
points of the each of the serum calcidiol levels (VitD-early, VitD-mid, and VitD-late).  
Cohen’s d was included in the statistical results. 
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Trends in Serum Calcidiol Levels 
Mean values for each of the calcidiol levels were determined and compared.  
Trends were examined in the calcidiol levels across the three time points and the 
relationship between the variables was determined.  Serum calcidiol levels over the three 
data collection time points were described and compared. 
Association Between Confounding Variables 
Pearson’s correlation coefficient was performed to evaluate the association 
between the confounding variables. This included the relationship between BG and age 
as well as the relationship between BG and BMI.  It also included the relationship 
between BMI and serum calcidiol levels, and the relationship between age and the serum 
calcidiol level.  
Protection of Human Subjects 
Protection of human subjects was assured.  The parent study received Institutional 
Review Board (IRB) approval by the University of North Dakota IRB and the Altru 
Health System IRB (Appendix A).  Informed consent (Appendix B) was obtained upon 
enrollment in the parent study which included the variables used in the secondary 
analysis.  Each participant received both written and verbal study information.  All were 
reassured that their medical care was the same whether or not they chose to participate in 
the study and that there was no obligation to participate.  All participants received the 
usual and customary care provided at their respective institutions. Since the goal of this 
study was to identify factors exclusive to pregnant women, enrollment of children was 
inappropriate. 
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IRB approval was submitted to perform the secondary analysis for this study to 
both UND and Altru Health System (Appendix A).  The project was approved by both 
agencies and considered an Exempt Review since it was a secondary analysis of a de-
identified data and the parent study had previously received IRB approval from both of 
these same IRBs.  According to Doolan and Froelicher (2009), a secondary analysis of an 
existing data set has the benefit of answering new research questions without putting 
participants at risk for any harm.  Further protection of human subjects is provided from 
the study design being a secondary analysis of a de-identified data set.  The information 
from the medical record was transcribed onto a Medical Record Abstraction Form 
(Appendix C) which did not include any identifying information about participants.  
Linkage between personal identification and unique identification number was known 
only to the principle investigator of the parent study.  The data set used in this secondary 
analysis was de-identified. 
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CHAPTER IV 
RESULTS 
Introduction 
The relationship between calcidiol levels at three predetermined points in 
pregnancy and the blood glucose level at 24-28 weeks gestation are reported.  This 
chapter reports the descriptive statistics for the sample participants and the results of the 
multiple regression analysis to answer each of the research questions.  A comparison of 
the calcidiol levels at each of the three collection points is reported.  The relationship 
between the variables used in the analysis was determined and reported in this chapter.  
Finally, the sample findings are compared with the regions, the state, and the nation. 
Descriptive Statistics of the Sample Participants 
This section describes the characteristics of the sample participants as it relates to 
the study variables.  Age and body mass index (BMI) are known confounding variables 
so are both presented.  Included is a normal distribution curve to illustrate how the 
sample aligns with a normal distribution.  Then the race of the sample participants is 
discussed and compared with that of the region (the state of North Dakota) and the nation 
(United States) as these demographics influence the generalizability of the findings from 
this sample. 
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Age 
The age range in years for the 52 participants in this study was between 18.8 and 
35.8 years with a mean of 25.9 (+ 4.18).  The normal childbearing age is between 18 and 
35 years and are within the expected range and normal distribution (Figure 4).   
 
 
 
 
 
 
 
 
 
 
Figure 4.  Distribution of age in sample. 
 
Table 2. Age and Body Mass Index. 
 Minimum  Maximum  Mean SD 
 
Age (years) 18.8 35.8 25.9 4.18 
BMI (kg/m2) 19.3 39.4 27.2 5.08 
 
Body Mass Index (BMI)   
The BMI was calculated for each of the participants.  As a group, the sample was 
in the overweight category which was determined because the mean BMI was 27.2 kg/m2 
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(+ 5.08).  BMI for the sample ranged from 19.3 to 39.40 kg/m2 which indicated the 
sample had women of normal BMI to women in the obese category for BMI.  There were 
no participants with a BMI in the underweight category.  A histogram was created to 
examine the frequency and distribution of the BMI values for the sample and the normal 
distribution Bell curve was place over the histogram (Figure 5). 
 
 
 
 
 
 
 
 
 
Figure 5.  Distribution of BMI in sample. 
Race of Study Participants 
The participants were asked to self-report their race with the following results: 
92.3% (n=48) Caucasian, 1.9% (n=1) Hispanic, and 5.8% (n=3) “mixed race” (Figure 6).   
The sample is closely representative of the population in North Dakota which has the 
following statistics on race: 89.6% Caucasian, 2.9 % Latino or Hispanic, 2 % black or 
African American, 5.4 % American Indian and Alaska Native, 1.2 % Asian, and 1.9 % 
“mixed race” indicating two or more races (United States Census Bureau, 2013).  There 
were no Native American or African-American participants.  This is important because 
Body Mass Index (BMI)  
N
um
be
r o
f P
ar
tic
ip
an
ts
 
56 
there is a higher prevalence of impaired glucose metabolism during pregnancy in Native 
American, African-American, and Hispanic women in the United States than in non-
Hispanic white women (Alzaim & Wood, 2013).  Barriers for minority participation in 
research studies include access to care, false perceptions, mistrust (Fisher & Kalbaugh, 
2011) and personal circumstances such as job flexibility or lack of awareness about the 
study (Wendler et al., 2006).   
 
Figure 6.  Race of sample and of North Dakota population. 
 
Figure 7.  Race of sample, North Dakota population, and of the United States. 
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Table 3.  Race of Sample and Population. 
Self-reported race  Sample North Dakota United States 
Total people 52 723,857 316,497,531 
White alone 92.3% (n=48) 89.6% 77.7% 
Latino or Hispanic 1.9% (n=1) 2.9% 17.1% 
Black/African American alone 0% 1.8% 13.2% 
American Indian/Alaska Native 0% 5.4% 1.2% 
Asian alone 0% 1.2% 5.3% 
Two or more races 5.8% (n=3) 1.9% 2.4% 
N=52 in study sample. North Dakota and United States per United States Census Bureau, 
2013 
 
The ethnicity was obtained for the sample, the population (North Dakota), and the 
nation (United States) and is reported above (Figure 7 and Table 11) (United States 
Census Bureau, 2013).  ANOVA was performed to ascertain if the study sample was 
representative of the population and the nation by testing for the difference between three 
groups (sample, North Dakota, and United States) the observed and expected proportions.  
There was not a statistically significant difference between groups at the p< .05 level, 
F(2, 15) = 01, p = .99.   
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Blood Glucose Levels 
Women are at risk for hyperglycemia during pregnancy due to the physiological 
changes which occur.  Blood glucose levels are obtained at mid-pregnancy in the normal 
course of prenatal care to screen for hyperglycemia.  For the purposes of this study, the 
blood glucose (BG) levels in mg/dl acquired at the routine mid-pregnancy test were 
collected through medical record abstraction.  The results are summarized below.  
In this sample, 5.8 % of the participants had a BG >140 mg/dl.  The mean for BG 
for the sample was 93.8 (+ 20.41 standard deviation).  As illustrated in Figure 8, this 
histogram of BG results is plotted with an overlay of a normal distribution Bell curve.  
This demonstrates that the scores generally follow a normal distribution.  There is a 
negative skew showing that the sample had a higher frequency of BG results which were 
less than 100 mg/dl.  It is visually apparent that the actual frequency of BG values was 
highest between 75 mg/dl and 100 mg/dl.  The significance of this finding will be 
discussed in Chapter V.   
Table 4.  Summary of Study Sample Findings for Blood Glucose. 
 Minimum Maximum  Mean SD 
BG (mg/dl) 59.0 157.0 93.8 20.42 
 
Serum Calcidiol Levels 
Blood was collected through venipuncture at three pre-determined points in this 
study to obtain serum calcidiol levels.  As discussed previously, serum calcidiol is the 
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Figure 8.  Distribution of blood glucose at 24-28 weeks of gestation in sample. 
usual laboratory test to determine vitamin D status.  For the purposes of this study, 
hypovitaminosis-D was defined as a serum calcidiol level of < 75 nmol/L.  
Prevalence of Hypovitaminosis-D in Sample 
Calcidiol levels for the sample for each of the collection points were examined.  
Only fifteen percent of the study participants had adequate calcidiol levels at all three of 
the points measured.  Hypovitaminosis-D was present in 81% of the participants at one or 
more points during the pregnancy and 67.3% with hypovitaminosis-D at all three 
measurement points.  In early pregnancy (VitD-early), 41 out of 52 women (78.9%) had 
hypovitaminosis-D.  In mid pregnancy (VitD-mid), 40 out of the 52 women (77%) had 
hypovitaminosis-D and in late pregnancy (VitD-late), 37 out of the 52 (71%) of the 
participants in the sample had hypovitaminosis-D (Figure 9).   
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Figure 9.  Number of participants by calcidiol level greater or less than 75 nmol/L.   
Range of Calcidiol Levels in Sample 
The range in the calcidiol levels demonstrates that some participants had levels 
much higher than 75 nmol/L.  VitD-early ranged 41.6-123.5 nmol/L, VitD-mid ranged 
36.5-154.3 nmol/L, and VitD-late ranged from 25.3-182.8 nmol/L.  The mean at each of 
these points for the sample was < 75 nmol/L which indicates that there were inadequate 
calcidiol levels at all points in pregnancy for this sample, as a whole.  The mean calcidiol 
level was 63.3 nmol/L for VitD-early, 66.3 nmol/L for VitD-mid, and 66.4 nmol/L for 
VitD-late (Table 5).    
Scatterplot of Participant and Target Calcidiol Levels 
Figure 10 visually demonstrates the calcidiol levels in nmol/L for each participant 
at each of the three collection points (VitD-early, VitD-mid, and VitD-late) compared to 
target level of greater than or equal to 75 nmol/L.  It is evident that the majority of serum 
calcidiol levels were less than the target level.  A few participants had at calcidiol levels 
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Table 5. Summary of Study Sample Findings of Calcidiol. 
 Minimum Maximum Mean SD 
Vit D-early  (nmol/L) 41.6 123.5 63.3 19.5 
Vit D-mid (nmol/L) 36.5 154.3 66.3 20.6 
Vit D-late (nmol/L) 25.3 182.8 66.4 24.5 
 
much lower than the target and a few had a calcidiol level much higher than the target 
level. The clustering of calcidiol levels between 40 and 75 nmol/L emerged as one of the 
limitations of the study.   
 
Figure 10.  Serum calcidiol levels for each participant at each time point.  
Serum Calcidiol Levels Over Time  
The mean of the calcidiol levels at each of the three collection points illustrates 
that the calcidiol level for the sample slightly increased over time (Figure 11).  The mean 
of the serum calcidiol level at 10-14 weeks gestation (VitD-early) was 63.3 nmol/L (+ 
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2.7).  The mean serum calcidiol level at 22-26 weeks gestation (VitD-mid) was 65.7 
nmol/L (+ 2.8).  The mean calcidiol level at 32-36 weeks of gestation (VitD-late) was 
65.9 nmol/L (+ 3.4).   
 
Figure 11.  Mean of serum calcidiol levels at each time point (VitD-early, VitD-mid, and 
VitD-late).  Error bars represent standard deviation. 
 
Frequency Distribution of Calcidiol Levels Over Three Collection Points 
Although the mean calcidiol levels at the three collection points have a 
mathematical difference of 2.6, the frequency distribution changes.  This distribution 
moves from being skewed to the left at VitD-early to a more normal distribution at VitD-
mid and VitD-late (see Figures 12, 13, and 14).  When all of the serum calcidiol levels 
are analyzed for frequency of occurrence, the distribution has a negative skew (Figure 15) 
with the majority of the levels lower than the recommended level of 75 nmol/L.    
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Figure 12.  Distribution of serum calcidiol levels at 10-14 weeks gestation (VitD-early). 
 
 
 
 
 
 
 
 
 
Figure 13.  Distribution of serum calcidiol levels at 22-26 weeks gestation (VitD-mid). 
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Figure 14.  Distribution of calcidiol levels at 32-36 weeks gestation (VitD-late) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15.  Distribution of All Calcidiol Levels in the Sample and Normal Curve.  Arrow 
is placed at Level of Adequate Calcidiol Level of 75 nmol/L  
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Correlation in Calcidiol Levels  
The trend in the calcidiol levels was analyzed to look for changes over the course 
of pregnancy.  Data were interval and normally distributed so the Pearson correlation was 
utilized.  There was a statistically significant correlation (p < 0.05) between the calcidiol 
levels at each point when compared to the other calcidiol levels for the participants in this 
sample.  However, there was not a statistically significant change in the calcidiol levels 
over the three collection points (table 6). 
Table 6.  Pearson Correlation Showing the Trend in Calcidiol Levels. 
 VitD-early VitD-mid VitD-late 
VitD-early ---   
VitD-mid .87* ---  
VitD-late .83* .95* --- 
* Significant at p < .05 
Research Questions and Analysis 
This section will focus on the three specific research questions for the study.  
Multiple regression analysis was utilized to look for a correlation between the calcidiol 
levels at each of the three predetermined points in time and the blood glucose levels at 
mid-pregnancy while controlling for the known confounding variables of age and BMI.  
The findings from analysis will also be presented.   
Correlation of Early Calcidiol Level With Mid Pregnancy Glucose Level 
R-squared is a statistical value which reflects how closely the data fit the 
regression line reported between zero (0% correlation) and one (100% correlation).  The 
66 
amount of variation explained by the regression analysis was 8.4% as evidenced by the R 
Square of 0.084 (Table 7).  There was not a statistically significant correlation between 
the calcidiol level at VitD-early and BG when controlling for the known confounding 
variables of age and BMI.  The null hypothesis was that there is no relationship between 
calcidiol levels at VitD-early and BG at 24-28 weeks gestation when controlling for age 
and BMI.  These results failed to reject the null hypothesis for this research question. 
Correlation of Mid Pregnancy Calcidiol Level With Mid Pregnancy Glucose Level 
The amount of variation explained by the regression analysis was 7.1% as 
evidenced by the R Square of 0.071 (Table 7).   There was not a statistically significant 
correlation between the calcidiol level at VitD-mid and BG when controlling for the 
known confounding variables of age and BMI.  The null hypothesis was that there is no 
relationship between calcidiol levels at VitD-mid and BG at 24-28 weeks gestation when 
controlling for age and BMI.  These results failed to reject the null hypothesis for this 
research question. 
Correlation of Late Pregnancy Calcidiol Level With Mid Pregnancy Glucose Level 
The amount of variation explained by the regression analysis was 7.5% as 
evidenced by the R Square of 0.075 (Table 7).  There was not a statistically significant 
correlation between the calcidiol level at VitD-late and BG when controlling for the 
known confounding variables of age and BMI.  The null hypothesis was that there is no 
relationship between calcidiol levels at VitD-late and BG at 24-28 weeks gestation when 
controlling for age and BMI.  These results failed to reject the null hypothesis for this 
research question. 
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Table 7.  R Square Analysis of VitD-early, VitD-mid, VitD-late With BG When 
Controlling for Age and BMI. 
 R R Square Std. Error 
VitD-early and BG .29 .08 20.1 
VitD-mid and BG .27 .07 20.2 
VitD-late and BG .27 .08 20.2 
Constants: Age, BMI 
Comparison of BG With Two Groups 
The data was divided into two groups, inadequate serum calcidiol levels and 
adequate serum calcidiol levels.  An inadequate serum calcidiol level was defined as 
being less than 75 nmol/L or the level of hypovitaminosis-D in this study.  The two 
groups were compared to see if there was a difference in the mean blood glucose levels 
between inadequate and adequate serum calcidiol levels.  This comparison was done for 
each of the time points (VitD-early, VitD-mid, and VitD-late).   
Comparison of BG With Inadequate or Adequate Calcidiol in Early Pregnancy 
An independent samples t-test was conducted to compare BG in conditions of 
inadequate and adequate calcidiol levels at VitD-early (using the customary p < .05).  The 
independent sample t test showed that the difference in the BG levels between the group 
with inadequate calcidiol levels (n = 41, M = 95.78, SD = 22.05) and the group with 
adequate calcidiol levels (N = 11, M = 86.36, SD = 10.20) was not statistically 
significant, t(50) = 1.37, p = .18.  These results suggest that there was not a statistically 
significant difference in the BG between the two groups, the group with inadequate 
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calcidiol levels and the group with adequate calcidiol levels at VitD-early (table 8).  
Cohen’s effect size (d = .47) suggested a moderate practical significance.   
An ANOVA was employed with similar results.  The difference between the 
means was not statistically significant at the .05 level (F= .71, df = 9, 40).  The critical 
value of F for the .05 level was 2.82.  Since the observed value of F was less than the 
critical value, the null hypothesis was not rejected. 
Table 8.  Mean Blood Glucose (BG) in mg/dl for Two Groups at 10-14 Weeks Gestation. 
 N Mean BG level Standard Deviation 
Inadequate calcidiol 41 95.78 22.05 
Adequate calcidiol 11 86.36 10.20 
 
Comparison of BG With Inadequate or Adequate Calcidiol in Mid Pregnancy 
An independent samples t-test was conducted to compare BG at 24-28 weeks of 
gestation in conditions of inadequate and adequate calcidiol levels at 22-26 weeks of 
gestation (VitD-mid). An independent sample t test showed that the difference in the BG 
levels between the group with inadequate calcidiol levels (N = 39, M = 95.67, SD = 
22.30) and the group with adequate calcidiol levels (N = 13, M = 88.15, SD = 12.29) was 
not statistically significant, t(50) = 1.15, p = .25.  These results suggest that there was not 
a statistically significant difference in the BG between the two groups, the group with 
inadequate calcidiol levels and the group with adequate calcidiol levels at 22-26 weeks of 
gestation (table 9).  Cohen’s effect size (d = .37) suggested a small to moderate practical 
significance.  
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An ANOVA was employed with similar results.  The difference between the 
means was not statistically significant at the .05 level (F = .28, df = 9, 40).  The critical 
value of F for the .05 level was 2.82.  Since the observed value of F was less than the 
critical value, the null hypothesis was not rejected 
Table 9.  Mean Blood Glucose (BG) for Two Groups at 22-26 Weeks Gestation. 
 N Mean BG level Standard Deviation 
Inadequate calcidiol 39 95.67 22.30 
Adequate calcidiol  13 88.15 12.29 
 
Comparison of BG With Inadequate or Adequate Calcidiol in Late Pregnancy 
An independent samples t-test was conducted to compare BG at 24-28 weeks of 
gestation in conditions of inadequate and adequate calcidiol levels at 32-36 weeks of 
gestation (VitD-late).  An independent sample t test showed that the difference in the BG 
levels between the group with inadequate calcidiol levels (N = 37, M = 95.51, 
SD = 21.19) and the group with adequate calcidiol levels (N = 15, M = 89.53, SD = 
18.33) was not statistically significant, t(50) = 0.96, p = .34.  These results suggest that 
there was not a statistically significant difference in the BG between the two groups, the 
group with an inadequate calcidiol level and the group with adequate calcidiol levels at 
32-36 weeks of gestation (Table 10).  Cohen’s effect size value (d = .29) suggested a 
small practical significance.   
An ANOVA was employed with similar results.  The difference between the 
means was not statistically significant at the .05 level (F= .22, df = 9, 40).  The critical 
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value of F for the .05 level was 2.82.  Since the observed value of F was less than the 
critical value, the null hypothesis was not rejected. 
Table 10.  Mean BG for Two Groups at 32 – 36 Weeks Gestation. 
 
N Mean BG level Standard Deviation 
Inadequate calcidiol 37 95.51 21.19 
Adequate calcidiol 15 89.53 18.33 
 
Specifically, these results suggest that there was not a statistically significant difference 
at any of the three points in pregnancy (VitD-early, VitD-mid, and VitD-late) in the BG 
level at 24-28 weeks gestation between the two groups based on inadequate calcidiol 
levels and adequate calcidiol levels.  
Confounding Variables 
Two confounding variables were often used in the literature review in the analysis 
of the relationship between serum calcidiol levels and blood glucose levels during 
pregnancy.  Those two confounding variables were maternal age and BMI.  Based on the 
literature review, both age and BMI were considered confounding variables in this study.  
These confounding variables were investigated separately below.  First, the relationship 
between BG and the confounding variables of age and BMI were investigated.  Then the 
relationship between the confounding variables of age and BMI and the serum calcidiol 
levels were examined. The Pearson’s r is a measure of effect size in this correlation.  
Effect size is small when r is 0.2, medium when r = 0.5, and large when r > 0.8 (Sullivan 
& Feinn, 2012).  Pearson’s r varies from -1 to 1 with the strength of the linear 
relationship getting stronger as the value is closer to 1 and weaker as the value 
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approaches zero.  The relationship can be either positive or negative which is represented 
by the positive or negative value of the integer. 
Relationship Between BG and the Variables of BMI and Age 
Since age and BMI are known confounders of BG metabolism, each of these 
factors (age and BG; BMI and BG) were examined independently.  Data were interval 
and normally distributed.  To determine if there was a relationship between BG and BMI, 
Pearson’s correlation was computed (Table 10).  There was not a statistically significant 
correlation between the BG and BMI, r = 0.25, n = 52, p = .07.  To determine if there was 
a relationship between BG and age, Pearson’s correlation was computed (table 11).  
There was not a statistically significant correlation between BG and age, r = 0.07, n = 52, 
p = .60.  In this sample, neither of the confounding variables of BMI and age had a 
statistically significant correlation with BG. 
Correlation Between BMI and Calcidiol Levels in Early, Mid, and Late Pregnancy 
First, a Pearson correlation coefficient was computed to assess the relationship 
between BMI and VitD-early.  There was a statistically significant negative correlation 
between the two variables of BMI and VitD-early, r = -0.43, n = 52,  
p = .001.  Second, a Pearson correlation coefficient was computed to assess the 
relationship between BMI and VitD-mid.  There was a statistically significant negative 
correlation between the two variables, BMI and VitD-mid, r = -0.30, n = 52,  
p = .03.  Finally, a Pearson correlation coefficient was computed to assess the 
relationship between BMI and VitD-late.  There was not a statistically significant 
relationship between the two variables of BMI and VitD-late, r = -0.20, n = 52, p = .16.  
Overall, there was a negative correlation found between BMI and the calcidiol level at 
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VitD-early and VitD-mid in pregnancy, but not found at VitD-late in pregnancy.  In other 
words, a higher BMI at the beginning of pregnancy was associated with a lower serum 
calcidiol level in early and mid-pregnancy (Table 11).    
Correlation Between Age and Serum Calcidiol Level 
A Pearson correlation coefficient was computed to assess the relationship between 
age and calcidiol levels at each of the three points.  There was not a statistically 
significant relationship at any of the three points (Table 11).  In summary, age did not 
have a statistically significant correlation with the calcidiol levels.   
Table 11.  Correlations All Factors. 
 
 Age VitD-early VitD-mid VitD-late BG BMI 
Age --      
VitD-early - .22 --     
VitD-mid - .23 .86* --    
VitD-late - .22 .80* .95* --   
BG - .07 - .16 - .12 - .12 --  
BMI .12 - .43* - .30* - .20 .25 -- 
* Correlation is significant at the 0.05 level. 
 
Summary 
 
The relationship between calcidiol levels in early, mid, and late gestation and 
blood glucose levels at 24-28 weeks gestation was investigated in a sample of pregnant 
women in an upper Midwestern community.  The known confounding variables of 
maternal age and body mass index (BMI) were included in the analysis.  
Hypovitaminosis-D during pregnancy was found in 81% of the women and there was not 
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a statistically significant change in serum calcidiol levels for the participants over time as 
measured by the three collection points.  Serum calcidiol levels were drawn at three 
predetermined points in pregnancy and described as VitD-early, VitD-mid, and VitD-late 
for the purposes of analysis.  The mean of the calcidiol level at VitD-early was 63.3 
nmol/L, the mean of the calcidiol level at VitD-mid was 65.7 nmol/L, and the mean 
calcidiol level at VitD-late was 65.9 nmol/L.  The mean calcidiol at each of these time 
points was below the recommended level of 75 nmol/L.  There was no evidence of a 
statistically significant relationship between the blood glucose level at 24-28 weeks of 
gestation and the calcidiol level at any of the predetermined points during pregnancy 
(VitD-early, VitD-mid, and VitD-late) when controlling for the confounding variables of 
age and BMI.  There was not a statistically significant difference in blood glucose levels 
between the group with inadequate calcidiol levels and the group with adequate calcidiol 
levels at any of the three points.   
The confounding variables were examined in relation to serum calcidiol levels 
and blood glucose levels.  There was a statistically significant inverse relationship 
between BMI and VitD-early (p < .05), and between BMI and VitD-mid (p < .05).  There 
was not a statistically significant between BMI and calcidiol levels in late pregnancy.  
Age did not have a statistically significant relationship with calcidiol at any point or with 
BMI.  A statistically significant relationship did exist between the calcidiol levels at 
VitD-early, VitD-mid, and VitD-late as well as between BMI and calcidiol levels.  The 
study results will be discussed further in Chapter V.   
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CHAPTER V 
DISCUSSION 
Introduction 
Chapter V briefly reviews the current study, presents the findings of this research, 
and integrates the results with the current literature. The discussion includes the rationale 
which influenced the research based decisions, the characteristics of the sample, and 
additional findings beyond the specific research questions.  This chapter concludes with 
limitations of the study, recommendations for further research, and implications for 
nursing. 
Summary of the Study 
This chapter begins with a brief overview of the problem.  The harmful effect of 
hyperglycemia in pregnancy is highlighted.  The potential mitigating influence of 
calcidiol on hyperglycemia is introduced.  
Overview of the Problem 
Hyperglycemia during pregnancy can result in adverse outcomes for the mother 
and the infant with both short term and long term consequences (Pridjian & Benjamin, 
2010).  The fetus obtains glucose through the placenta by facilitated diffusion (Day, 
Cleal, Lofthouse, Hanson, & Lewis, 2013) and is therefore dependent upon maternal 
blood glucose levels (Barta & Drugan, 2010).  Even though fetal BG levels are 15 mg/dl 
lower than the maternal BG levels (Gabbe et al., 2012, p. 542), increased maternal BG 
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levels have been associated with fetal effects such as overgrowth (The HAPO Study, 
2009).  Intrauterine hyperglycemia not only results in this abnormal fetal growth but also 
appears to predispose the offspring for abnormal glucose tolerance later in life (Clausen 
et al., 2008; Luo et al., 2010).  The persistent effects of hyperglycemia in pregnancy may 
even have generational effects (Vambergue & Fajardy, 2011).   
Interventions which can reduce the harm of hyperglycemia are needed.  There is 
growing evidence that vitamin D influences glucose metabolism.  Hypovitaminosis-D has 
been associated with impaired glucose metabolism in non-pregnant and pregnant subjects 
which is of interest since hypovitaminosis-D can be treated through use of supplements 
(Alzaim & Wood, 2013).  However, the findings on the effects of vitamin D on maternal 
glucose levels during pregnancy are inconsistent leading to the need for further research.   
Purpose Statement 
The purpose of this study was to determine the relationship between calcidiol 
levels collected in early, mid, and late pregnancy and blood glucose levels in mid 
pregnancy in a sample of women in an upper Midwestern region of the United States.  A 
quantitative, correlational design was used in a secondary analysis to ask new questions 
of an existing data set.  Calcidiol influences glucose metabolism in the non-pregnant 
population (Alfonso et al., 2009; Mathieu et al., 2005; Pittas et al., 2006; Tohidi et al., 
2013) and this study investigated the influence of calcidiol on glucose metabolism in the 
pregnant population.  The significance of this relationship is that it may inform an 
understanding of the effect of calcidiol on glucose metabolism in pregnancy.  By 
identifying the correlation between calcidiol and glucose levels, there is the potential to 
mitigate hyperglycemia in pregnancy and improve the health of infants and mothers.  The 
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working hypothesis for this study was that there would be an inverse relationship 
between calcidiol during pregnancy and mid pregnancy blood glucose levels.  
 In the professional literature, both maternal age and body mass index (BMI) were 
considered to be confounding variables in the analysis of calcidiol and BG (Clifton-Bligh 
et al., 2008; Maghbooli et al., 2008).  Consistent with the literature, both BMI and 
maternal age were considered confounding variables in the current study.  This research 
was designed to answer the following questions on the relationship between calcidiol and 
BG in the sample group: 
Research Questions 
This section begins with the research questions answered by this study.  The 
methodology is then reviewed and the major findings are presented.  The research 
questions were: 
1. Is there a correlation between the calcidiol level at 10-14 weeks gestation and 
the BG level at 24-28 weeks gestation when controlling for the known confounding 
variables of age and pre-pregnancy body mass index (BMI)? 
2. Is there a correlation between calcidiol level at 22-26 weeks gestation and the 
BG level at 24-28 weeks gestation when controlling for the known confounding variables 
of age and BMI? 
3. Is there a correlation between the calcidiol level at 32-36 weeks gestation and 
the BG level at 24-28 weeks gestation when controlling for the known confounding 
variables of age and BMI? 
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Review of the Methodology  
This exploratory study was done to examine the relationship between serum 
calcidiol levels at early, mid, and late pregnancy and the BG levels at 24-28 weeks 
gestation.  A secondary analysis was completed on a data set from a prospective study 
which used a convenience sample of 52 pregnant women.  All participants were 
nulliparous women enrolled at less than 14 weeks gestation to allow the early pregnancy 
calcidiol level collected at 10-14 weeks gestation.  The sample population was drawn 
from a community in the upper Midwestern United States at a latitude of 47.93° N.  
People living at this latitude are at risk for hypovitaminosis-D because the cutaneous 
production of vitamin D is limited due to the UV spectrum (Holick & Chen, 2008; 
Schroth et al., 2005).  The population of the state has a 31% obesity rate (Levi, Segai, 
Laurent & Raybum, 2014) which is significant because obesity is associated with 
hypovitaminosis-D (Hemmings, 2013; Schwanlfenberg, 2007).   
In the professional literature, both maternal age and body mass index (BMI) were 
considered to be confounding variables when investigating calcidiol and BG levels 
(Clifton-Bligh et al., 2008; Maghbooli et al., 2008).  Lower calcidiol levels can be a result 
of increased BMI and increasing age can result in lower calcidiol levels (Collins-Fulea et 
al., 2012; Holmes et al., 2009; Prentice, 2008; Wicherts et al., 2011).  Concurrently, both 
maternal age and BMI can influence maternal glucose levels.  Maternal age greater than 
30 years and maternal BMI in the obese category (> 30) are risk factors for 
hyperglycemia in pregnancy (Soheilykhah et al., 2010; Zhang et al., 2008).  Consistent 
with the literature, both BMI and maternal age were considered confounding variables in 
this study. 
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Major Findings 
There was no evidence of a statistically significant relationship between calcidiol 
levels at any of the three points and the blood glucose levels when controlling for the 
known confounding variables of BMI and age (R square .084, .071, and .075 
respectively).  However, the high percentage of hypovitaminosis-D resulted in inadequate 
variance in this sample to show a difference, if one does exist.  Eighty-one percent of the 
participants had hypovitaminosis-D at some point during pregnancy and 67% had 
hypovitaminosis-D at all three points during pregnancy.   
There was a statistically significant correlation among the calcidiol levels at the 
three collections points (p < 0.01).  In other words, maternal calcidiol levels did not 
statistically change over the course of pregnancy in this sample.  The women who had 
hypovitaminosis-D in early pregnancy continued to have hypovitaminosis-D in mid and 
late pregnancy.  These findings suggest that women who have hypovitaminosis-D in 
pregnancy may not experience improvement in vitamin D levels over the course of 
pregnancy. 
There was a statistically significant inverse relationship between BMI and the first 
(p < 0.01) and second (p < 0.05) calcidiol levels.  These results suggest that women with 
a higher BMI may need additional vitamin D during pregnancy.  Cumulatively, these 
findings suggest that women in the upper Midwest may not be getting adequate vitamin 
D during pregnancy, especially those with a higher BMI. 
Findings Related to the Literature 
Each of the three research questions are discussed below and integrated into the 
literature.  First, the confounding variables of maternal age and body mass index are 
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briefly discussed.  This is followed by a more extensive discussion on the more complex 
topics of blood glucose and calcidiol.  
Maternal Age 
Maternal age is a known confounding variable in the relationship between 
calcidiol levels and BG levels.  Increasing maternal age can result in lower calcidiol 
levels (Collins-Fulea et al., 2012; Holmes et al., 2009; Prentice, 2008; Wicherts et al., 
2011).  Maternal age greater than 30 years is a risk factors for hyperglycemia in 
pregnancy (Soheilykhah et al., 2010; Zhang et al., 2008).  The age range in this study was 
18.82 years to 35.80 years with a mean age of 25.87 (+/- 5.13) years.  There was not a 
statistically significant correlation between maternal age and blood glucose (p = .31) nor 
was there a statistically significant relationship between maternal age and the calcidiol 
level at 10-14 weeks gestation (p = .12), maternal age, maternal age and the calcidiol 
level at 24-28 weeks gestation (p = .10), or maternal age and the calcidiol level at 32-28 
weeks gestation (p = .12).   
Body Mass Index 
Excess weight in early pregnancy is associated with adverse complications and 
places the woman in the high risk category for perinatal management (Bautista-Castano, 
Henriquez-Sanchez, Garcı´a-Herna´ndez, & Serra-Majem, 2013).  A higher BMI is 
associated with an increased risk of insulin resistance and impaired glucose metabolism 
during pregnancy (Alberico et al., 2014; Power & Thomas, 2011; Rao, Disraeli & 
McGregor, 2004).  A body mass index (BMI) below 18.5 is considered underweight, 18.5 
- 24.9 is categorized as normal, 25.0 – 29.9 is in the obese category, and 30.0 and above 
is obese (CDC, n.d.).   
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Since there is a predictable and expected weight gain during pregnancy, the 
participant’s height and either pre-pregnancy weight or first documented weight in early 
pregnancy were used to calculate the pre-pregnancy BMI using the formula: weight (kg) / 
[height (m)]2  (CDC, n.d.).  In this study, the mean BMI was 27.21 which is in the 
overweight category.  Two of the three women in the study sample with hyperglycemia 
had a BMI which put them in the overweight category and the third had a BMI in the 
obese category.   
BMI is considered a confounding variable for serum calcidiol levels because 
vitamin D is fat soluble and stored in adipose tissue (Achkar et al., 2015; Aloia, 2011; 
Hemmings, 2013; Holick, 2004). As the amount of body fat increases, there is 
progressive decrease in serum calcidiol levels (Arunabh, Pollack, Yeh & Aloia, 2003) 
from irreversible sequestration of vitamin D in the adipose tissue which leads to 
hypovitaminosis-D, especially if the BMI is > 30 (Hemmings, 2013; Schwalfenberg, 
2007).  The vitamin D insufficiency associated with obesity may occur because the 
increased amount of subcutaneous adipose tissue may prevent release of stored vitamin D 
(Wortsman, Matsuoka, Chen, Lu & Holick, 2000).  A statistically significant inverse 
relationship was found between the calcidiol level at the first and second points during 
pregnancy and the BMI.  Pearson’s correlation between VitD-early (the calcidiol level at 
10-14 weeks gestation) and BMI was -0.43 (p = .001).  Pearson’s correlation between 
VitD-mid (the calcidiol level at 24-28 weeks gestation) and BMI was -0.30  
(p = .03).  Pearson’s correlation between VitD-late (the calcidiol level at 32-36 weeks 
gestation) and BMI was -0.20 (p = .16).  These findings are is consistent with the findings 
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of other researchers who have found an inverse association between calcidiol levels and 
BMI (Burris et al., 2012; Ding et al., 2014; Zhang et al., 2008).   
Burris et al. (2012) had similar findings in their research with a large sample size 
in a healthy population.  They considered the possibility that hypovitaminosis-D might be 
part of the causal pathway between obesity and gestational diabetes mellitus.  They 
suggest that vitamin D supplementation for obese women in pregnancy might decrease 
the risk of developing GDM.   Although they did not study pregnant women, Ding et al. 
(2014) found a negative association between BMI and serum calcidiol levels (p= 0.002) 
in a cross-sectional study conducted in healthy Chinese adults with normal glucose 
metabolism. Zhang et al. (2008) completed a nested case controlled study examining 
factors related to the development of GDM.  They found that maternal serum calcidiol 
levels were inversely associated with pre-pregnancy BMI (p =.01 in controls; p = .04 in 
those with GDM).  The study methodologies, population studied, and sample sizes all 
differed in these studies but had similar results in finding an inverse association between 
serum calcidiol levels and BMI in healthy people. 
North Dakota ranks 14th in the United States for adult obesity with 31% of adults 
in the state classified in this category (Centers for Disease Control and Prevention, 2012).  
Grand Forks County where the most of the participants for this study resided, has a 
median adult obesity rate of 7.1% (CDC, 2012).  Since the people in this region already 
ranks high in obesity, there needs to be heightened awareness of importance of adequate 
vitamin D in pregnancy for women with a higher BMI. 
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Blood Glucose 
Blood glucose is an essential element in this study because hyperglycemia during 
pregnancy can result in harm.  The effects of hyperglycemia in pregnancy are presented 
first.  This is followed by a discussion of blood glucose as it pertains to the current study. 
Effects of Hyperglycemia in Pregnancy 
There are multiple dimensions to hyperglycemia which can impact the mother and 
her baby including an increased risk of an adverse outcome to the pregnancy (Santamari 
et al., 2011) because blood glucose levels during pregnancy have a significant influence 
on both maternal and fetal morbidity (Flack, Ross, Ho, & McElduff, 2010) and long-term 
effects exist beyond the newborn period and may contribute to the increasing rates of 
obesity, glucose intolerance, and diabetes in the future (Lehnen et al., 2013; Luo et al., 
2010; Ryan, 2012; Veeraswamy et al., 2012).   
Rationale for Choice of Blood Glucose Level  
Consistent with the American Diabetes Association (2015), a normal blood 
glucose level at 24-28 weeks of <140 mg/dl was considered to be normal and a level 
greater than this was considered hyperglycemia.  Much of the professional literature 
reports on impaired glucose metabolism in pregnancy or on GDM but not specifically on 
hyperglycemia in pregnancy.  For the purposes of this study, GDM or impaired glucose 
metabolism were considered to be proxy to hyperglycemia in pregnancy. 
Blood Glucose in This Study 
There were a total of 52 study participants.  Three participants (5.8%) had a blood 
glucose level > 140 mg/dl which was the defining point for hyperglycemia.  This level is 
consistent with other results in the region.  In 2013, 5.1% (n=544) North Dakota residents 
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had a diagnosis of GDM during pregnancy according to birth certificate information from 
the Division of Statistics at the ND Department of Health (personal communication, Dr. 
S. Pickard and C. Barth, 3/26/2015).  The Pregnancy Risk Assessment Monitoring 
System (PRAMS) survey of 2002 (the last year of participation by the state of North 
Dakota) reported that 6.8% of the survey respondents in North Dakota had 
hyperglycemia during pregnancy (DeSisto, Kim, & Sharma, 2014).  DiSisto et al. (2014) 
reported that there was a 9.2% prevalence of hyperglycemia during pregnancy in the 
United States using PRAMS data and birth certificate information from the seventeen 
states that participated in 2010.  Therefore, the study findings are closely representative 
of the state where the participants reside but is not representative of the nation (Figure 
14).   
 
Figure 16.  Rates of hyperglycemia in the study sample compared to PRAMS results for 
North Dakota and the United States.  (DeSisto et al., 2014) 
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Calcidiol 
The serum calcidiol level is used to assess vitamin D status (Yap et al., 2014) yet 
consensus has not been reached on what level of calcidiol is adequate for health (Aloia, 
2011; Holick, 2007; Holick et al., 2011; Ross et al., 2011).  The development of dietary 
reference intakes by the Institute of Medicine (IOM) was a result of a joint effort by the 
governments of the United States and Canada (Aloia, 2011).  The appointed committee of 
scientists reviewed the literature and based their recommendations from the evidence of 
vitamin D for bone health yet determined there was insufficient evidence for causality or 
a dose-response relationship for any extra-skeletal vitamin D indications (Aloia, 2011; 
IOM, 2011).  The IOM also concluded that a calcidiol level > 50 nmol/L is adequate and 
that vitamin D inadequacy has been overestimated in North America (IOM, 2011). 
Subsequently, The Endocrine Society responded by publishing a Clinical Practice 
Guideline with several points of disagreement with the IOM (Hollis & Wagner, 2013; 
Rosen et al., 2012) which then resulted in additional professional discourse in the 
literature.  The Endocrine Society Clinical Practice Guideline was developed by a task 
force with input from society members and focused on prevention of vitamin D 
deficiency through evaluation and treatment (Holick et al., 2011).  Pramyothin and 
Holick (2012) bring clarity to the differences by explaining the two organizations reflect 
different views of the evidence and different goals.  In the future, vitamin D studies will 
guide recommendations based on patient outcomes as a result of various calcidiol levels 
(Pramyothin & Holick, 2012).  The Endocrine Practice Guideline recommends 600-1000 
IU in pregnancy for women between 14-18 years of age and 1500-2000 IU for pregnant 
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women ages 19-50 years of age (Pramyothin & Holick, 2012).  The Endocrine Society 
endorses a serum calcidiol of > 75 nmol/L to be adequate (Holick et al., 2011).  
Recommended Daily Allowance for Calcidiol 
The IOM set the recommended daily allowance for vitamin D at 600 IU daily for 
persons ages 1 – 70 assuming minimal daily sunlight exposure and with no change in the 
recommended daily allowance in pregnancy (Ross et al., 2011).  The Endocrine Society 
recommends pregnant women take at least 600 IU of vitamin D daily and recognize that 
some pregnant women may need 1500-2000 IU daily to maintain adequate calcidiol 
levels (Holick et al., 2011).  Schwalfenberg (2007) recommends individualized dosing of 
vitamin D supplements to restore serum calcidiol levels to >80 nmol/L and reported that 
both insulin production and sensitivity improved from this intervention.  However, 
according to Schwalfenberg (2007), between 1800-2200 IU of vitamin D is needed daily 
to achieve and maintain serum calcidiol levels at the target of >80 nmol/L. 
Rationale for Choice of Calcidiol Level 
Hollis et al. (2012) questioned if the recommendations for daily intake of vitamin 
D need to change during pregnancy because optimization of the active form of vitamin D, 
calcitriol, occurs only after the circulating calcidiol levels reach 100 nmol/L.  The IOM 
used skeletal benefits alone to develop their guidelines (Aloia, 2011; Pramyothin & 
Holick 2012) while The Endocrine Society endorses a serum calcidiol level of 75 nmol/L 
for the non-skeletal benefits in their published Clinical Guideline (Holick et al., 2011).  
Since the influence of vitamin D for this research is for one of the non-skeletal benefits of 
vitamin D, a serum calcidiol level less than 75 nmol/L was considered to be 
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hypovitaminosis-D.  In this study, the mean calcidiol level for VitD-early was 63.32, for 
VitD-mid was 65.73, and for VitD--late) was 65.89.   
Table 12.  Comparison of Recommended Serum Calcidiol Levels for Pregnant Women 
Ages 18-50 years.  
 
 
 
Calcidiol status 
 
 
Institute of 
Medicine 
 
NIH Office 
of Dietary 
Supplements 
 
United States 
Endocrine 
Society 
 
Calcidiol deficiency < 30 nmol/L < 30 nmol/L < 50 nmol/L 
Inadequate/insufficient  < 40 nmol/L 30-50 nmol/L 52.5-72.5 
nmol/L 
Considered adequate > 50 nmol/L > 50 nmol/L  > 75 nmol/L 
No additional benefit for 
bone health 
> 75 nmol/L Not applicable Not applicable 
Potential adverse effects > 125 nmol/L > 125 nmol/L  >150 nmol/L 
Holick et al., 2011; IOM, 2011 
Hypovitaminosis-D in North Dakota 
Hypovitaminosis-D is of particular concern for people in North Dakota.  
Researchers at the Grand Forks Human Nutrition Research Center (GFHNRC) evaluated 
the diets of 224 women aged 40 years or more who had participated in a study at the 
center.  Based on their results, they reported the average intake of vitamin D was 135 IU 
per day and concluded that most people living in the state are at risk for hypovitaminosis 
D (Nielsen, 2011).  The people who participate in the GFHNRC studies live in 
communities near the GFHNRC and therefore are at risk for inadequate daily sunlight 
exposure.  Americans living in the northern latitudes do not have adequate daily exposure 
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to sunlight and therefore need vitamin D supplements or fortified foods to meet the 
minimum daily intake of vitamin D.   
Influence of the Placenta on Calcidiol 
Pregnancy is a unique physiological condition because there is a placenta and a 
fetus. Physiological changes during pregnancy affect both vitamin D metabolism and 
transport resulting in an increase the circulating levels of calcitriol with little effect on the 
serum calcidiol levels.  The mechanisms for these effects are not fully understood but 
both the kidney and the placenta contribute to the increased levels of calcitriol (Brannon 
& Picciano, 2011).  The placenta has a functional endocrine system and is a known site 
for activation of calcidiol (Anderson et al., 2014; Barrera, Avila, Hernández, & Méndez, 
2008).  It contains extra-renal cells which can transform calcidiol from the maternal 
circulation into calcitriol.  It has been proposed that the placental intervillous space could 
potentially be a site for admixture of maternal circulation calcidiol and the calcitriol from 
the fetal side of placental circulation (Adams & Hewison, 2012; Brannon & Picciano, 
2011).  It is yet unknown if this contributes to the calcitriol in maternal or fetal 
circulation (Adams & Hewison, 2012).  Even though serum calcidiol levels do not 
increase in pregnancy, calcitriol levels gradually increase for some unknown reason, 
starting at about 10-12 weeks until almost double in near the end of pregnancy (Alzaim & 
Wood, 2013; Brannon & Picciano, 2011). 
In laboratory studies, the overall data indicates that the human placenta not only 
has the components required for vitamin D signaling, it also has the enzymes to 
synthesize large amounts of calcitriol which is secreted by the placenta (Anderson et al., 
2014; Avila et al., 2004; Shin et al., 2010).  In addition, the kidneys increases the 
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synthesis of calcitriol during pregnancy and this higher concentration in maternal serum 
which could also facilitate transfer to the fetal circulation. When calcidiol concentration 
is diminished such as during vitamin D deficiency, the healthy kidney increases calcitriol 
production (Adams & Hewison, 2012).  These factors may contribute to the fact that the 
maternal serum calcitriol levels increase until they are two-fold higher in the third 
trimester than in women who are not pregnant (Parlea et al., 2011).   
Calcidiol in This Study  
In this study, 81% of the participants had hypovitaminosis-D at one or more 
points during pregnancy and 67% had hypovitaminosis-D at all three points.  It is unclear 
how these findings should be interpreted because only two previous studies were 
available reporting the vitamin D status for the region to compare with the findings in this 
sample.  Anderson et al. (2014) studied vitamin D and pregnancy outcomes found 
hypovitaminosis-D in 69.5% of participants living in the same area of the Midwest.  
Thiele (2014) completed research in the same region and found that 61% (8 of 13) of the 
participants in the study had hypovitaminosis-D at enrollment.  People who live at 
latitudes higher than 37 N are especially at risk for hypovitaminosis-D because the angle 
of the sun’s rays prevents adequate UVB radiation for synthesis of vitamin D through the 
skin (Bodnar et al., 2007).  Anderson et al. (2014) did not find that season of the year 
significantly influence serum calcidiol level or pregnancy outcomes.   
Serial Calcidiol Levels During Pregnancy 
Few studies were found in the literature which showed serial calcidiol levels 
during pregnancy which approximated the time frames in this study.  Ainy, Ghazi, and 
Azizi (2006) noted hypovitaminosis-D of 48 Iranian women in Tehran; yet, they did find 
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that serum calcidiol levels increased as pregnancy progressed through the three 
trimesters.  Marwaha et al. (2011) found a high prevalence of hypovitaminosis-D 
throughout the course of pregnancy for women in India.  Zhao et al. (2014) found 
hypovitaminosis-D in all three trimesters when retrospectively testing samples obtained 
from 50 women during pregnancy in Northeast China where they did not take vitamin 
supplements.  Hypovitaminosis-D was prevalent at all three points in these studies 
showing that the calcidiol levels did not adequately improve over time and that 
hypovitaminosis D was a major problem during pregnancy (Zuhur, Erol, Kuzu, & 
Altruntas, 2013).  This supports the findings of Schroth et al. (2005) who stated intake of 
vitamin D fortified foods or regular multivitamins may not increase the serum calcidiol to 
an adequate level for maternal and fetal health.  Tande et al. (2013) recommend 
interventions to target the nutritional status of the mother in early pregnancy because they 
provide an opportunity to improve pregnancy outcomes during this critical period for 
development of both the fetus and the placenta.  Improving hypovitaminosis D is of 
paramount importance and readily amenable by treating with vitamin D supplements 
(Alzaim & Wood, 2013; Zuhur et al., 2013). 
Study Findings 
In this study sample the percentage of women with hyperglycemia in pregnancy 
was 5.8%.  This was in spite of the level of hypovitaminosis-D, the lack of a statistically 
significant change in serum calcidiol levels, and the mean BMI of 27.21 which was in the 
overweight category.  According to the Pregnancy Risk Assessment Monitoring System 
(PRAMS) report, the rate of hyperglycemia for the state (North Dakota) was 5.1% and 
for the nation was 9.2% (DeSisto et al., 2014).  The percentage of women with 
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hyperglycemia during pregnancy in the study sample was similar to population of the 
state but not of the nation.  This limits the generalizability of the study findings to the 
region. 
Table 13.  Research Findings of Calcidiol Levels at More Than One Point in Pregnancy. 
  First trimester 
or VitD-early 
 
Second trimester 
or VitD-mid 
 
Third trimester 
or VitD-late 
 
Ainy, Ghazi, Azizi, 2006 51.5 nmol/L 64.3  nmol/L 71.8  nmol/L 
Marwaha et al., 2011 23.4 nmol/L 25.7  nmol/L 27.7  nmol/L 
Zhao et al., 2014 28.29 nmol/L 39.23 nmol/L 40.03 nmol/L 
This study 63.32 nmol/L 65.7  nmol/L 65.9  nmol/L 
 
 
 
Figure 17.  Calcidiol levels at three points in pregnancy.  
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Calcidiol and Blood Glucose in Pregnancy 
There are conflicting findings on the influence of calcidiol on blood glucose 
metabolism in pregnancy and inconsistent methodology utilized in the research.  Some 
investigators have reported a relationship between hypovitaminosis-D during pregnancy 
and impaired glucose metabolism (Alzaim & Wood, 2013; McLeod et al., 2011; Shin et 
al., 2010) or an increased risk for gestational diabetes mellitus (Aghajafari et al., 2013; 
Cho et al., 2013; Parlea et al., 2011; Zhang et al., 2008 ).  Other researchers report they 
found an inverse relationship between vitamin D levels and fasting glucose in pregnant 
women (Burris et al., 2102; Clifton-Bligh et al., 2008; Maghbooli et al., 2008; 
Soheilykhah et al., 2010).  In contrast, when pregnant women had mostly adequate 
calcidiol levels, researchers did not find a relationship between maternal calcidiol levels 
and hyperglycemia (Baker et al., 2012; Tomedi et al., 2013).  Poel et al. (2012) also 
completed a systematic review and meta-analysis and found a significant inverse 
association between calcidiol and the incidence of impaired glucose tolerance in 
pregnancy but state a causal relationship has not been proven.   
In pregnancy, screening for hyperglycemia is done in mid-pregnancy as part of 
routine prenatal care because the gestational steroid hormones cause a gradual increase in 
peripheral insulin resistance which intensifies after mid-pregnancy (Alzaim & Wood, 
2014).  This acquired insulin resistance in a normal human pregnancy is estimated to be 
between 40% and 70%, predominantly in the last trimester (Pridjian & Benjamin, 2010; 
Retnakaran et al., 2008; Yap et al., 2014).  The insulin resistance results in a significant 
need for additional insulin secretion, therefore women with impaired pancreatic β-cell 
reserve pre-pregnancy are at risk for developing impaired glucose metabolism such as 
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occurs in gestational diabetes (Retnakaran et al., 2008; Yap et al., 2014).  The 
combination of increasing insulin resistance, reduced pancreatic β-cell function, and 
insufficient secretion of insulin leads to the hyperglycemia which some women 
experience during pregnancy (Pridjian & Benjamin, 2010; Wang et al., 2013).   
Some investigators found evidence which links hypovitaminosis-D and abnormal 
glucose metabolism in pregnancy (Alzaim & Wood, 2013; Cho et al., 2013; Clifton-Bligh 
et al., 2008; Pittas & Dawson-Hughes, 2010; Maghbooli et al., 2008).  Asemi et al. 
(2013) found that vitamin D supplementation during pregnancy had a beneficial effect on 
glycemic control in women with impaired glucose metabolism.  Yap et al. (2014) 
investigated the effects of vitamin D supplements in either 400 IU or 5000 IU daily in 
pregnant women with calcidiol < 80 nmol/L on the maternal glucose levels during an oral 
glucose tolerance test at 26-28 weeks gestation.  They reported that the high dose vitamin 
D intervention starting at a mean of 14 weeks gestation did not improve the maternal 
glucose levels (Yap et al., 2014).  These two examples illustrate the inconsistent findings 
noted by researchers on the relationship between vitamin D and hyperglycemia in 
pregnancy (Alzaim & Wood, 2013; Collins-Fulea et al., 2012; Dror et al., 2011).  Some 
clarity may emerge when looking at the findings based on gestational weeks at the time 
of the serum calcidiol level to see how the timing of this level relates to impaired glucose 
metabolism.    
Multiple Linear Regression Analysis 
According to the literature, both maternal age and BMI are known confounders 
for serum calcidiol levels and for hyperglycemia in pregnancy.  A multiple linear 
regression is a statistical model which can be used to separate the relationship of interest 
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from the confounding variables (Pourhoseingholi, Baghestani & Vahedi, 2012).  Because 
of this, a multiple linear regression was employed to control for age and BMI in the 
analysis of the relationship between calcidiol levels and BG for each of the time points.  
In the analysis, calcidiol levels (VitD-early, VitD-mid, and VitD-late), BMI, and age 
were the independent variables and BG was the dependent variable. The results of the 
findings for each time point are discussed separately and integrated with the current 
literature.  
Relationship Between Calcidiol in Early Pregnancy and Blood Glucose 
Is there a correlation between the calcidiol level at 10-14 weeks gestation (VitD-
early) and the BG level at 24-28 weeks gestation when controlling for the known 
confounding variables of age and pre-pregnancy BMI?  The three participants who had 
hyperglycemia at 24-28 weeks gestation had hypovitaminosis-D at VitD-early.  R square 
was 0.084 which means the amount of variation explained in the regression was 8.4% 
indicating there does not appear to be a strong correlation VitD-early and BG at 24-28 
weeks in this sample.   
The current study did not find a statistically significant relationship between 
calcidiol levels in early pregnancy and BG levels at 24-28 weeks gestation.  These 
findings are similar to Fernandez-Alonso et al. (2012) and Makgoba et al. (2011) who 
both found high levels of hypovitaminosis-D in their participants yet no association with 
hyperglycemia.  Tomedi et al. (2013) did not find an association between calcidiol levels 
at < 16 weeks gestation and BG in non-smoking women who participated in their study; 
however, they did find an inverse association between first trimester calcidiol levels and 
BG at 24-28 weeks gestation in participants who were smokers.  Baker et al. (2013) did 
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not find a relationship between calcidiol levels in early pregnancy and BG at 24-28 weeks 
gestation, but a limitation of that study was the low prevalence of hypovitaminosis-D in 
their participants.   
In contrast, Lacroix et al. (2013) investigated calcidiol levels and insulin 
resistance, and reported a modest association between first trimester hypovitaminosis-D 
and insulin resistance at 24-28 weeks gestation, which suggests a higher risk for 
hyperglycemia.  Zhang et al. (2008) concluded that hypovitaminosis-D in early 
pregnancy (< 16 weeks) was associated with an increased risk for hyperglycemia when 
controlling for maternal age and BMI.  They report that the women in their study who 
had hyperglycemia were older and heavier than the normoglycemic women in their 
sample.  Parlea et al. (2011) identified cases of GDM and matched them to controls, then 
analyzed frozen, stored serum samples which had been collected from those women at 
15-18 weeks gestation.  The groups below and above the fourth quartile for calcidiol 
levels (73.5 nmol/L) were compared.  They report a significant association between 
calcidiol levels <73.5 nmol/L at 15-18 weeks gestation after controlling for maternal age, 
BMI, and race.   
The high prevalence of hypovitaminosis-D in the current study resulted in limited 
variation in the sample which could have prevented evidence of a relationship between 
calcidiol and BG, if one did exist.  The sample sizes, methods, and early pregnancy 
calcidiol levels among the research varied and these inconsistencies are a limitation when 
comparing these studies.  The findings in the literature are not conclusive or consistent.  
To summarize these findings including the current study, there was no statistically 
significant relationship found between hypovitaminosis-D in early pregnancy and BG at 
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24-28 weeks gestation; however, hypovitaminosis-D possibly increases the diagnosis of 
GDM. 
The hypothesis for the current study was that there would be an inverse 
relationship between calcidiol levels in early pregnancy and the BG level at 24-28 weeks 
gestation.  The state of the science does not definitively prove nor disprove this 
hypothesis.  Baker et al. (2012) reported that 73% of the participants in their sample had 
serum calcidiol levels > 75 nmol/L which may have prevented finding the relationship 
between calcidiol levels in early pregnancy and BG at 24-28 weeks gestation.  Their 
findings included a recommendation that research be done with participants who had a 
high prevalence of hypovitaminosis-D to determine if there was a correlation between 
calcidiol levels in early pregnancy and BG levels at 24-28 weeks gestation.  The current 
study addresses that recommendation. The sample for the current study had a high 
prevalence of hypovitaminosis-D in early pregnancy and there was not a statistically 
significant correlation to hyperglycemia at 24-28 weeks.  Based on the current science, 
there is no evidence of a statistically significant relationship between calcidiol levels in 
early pregnancy and BG levels at 24-28 weeks gestation. 
Relationship Between Calcidiol in Mid Pregnancy and Blood Glucose 
Is there a correlation between calcidiol level at 22-26 weeks gestation (mid) and 
the BG level at 24-28 weeks gestation when controlling for the known confounding 
variables of age and BMI?  The three the study participants who had hyperglycemia in 
mid pregnancy also had hypovitaminosis-D at 22-26 weeks (VitD-mid) in addition to 
early pregnancy, as noted above.  The relationship between VitD-mid and BG was 
analyzed controlling for maternal age and BMI with an R square of 0.071 which means 
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the amount of variation explained by the model is 7.1%.  There does not appear to be a 
strong correlation between the calcidiol levels at VitD-mid and the BG levels at 24-28 
weeks of gestation in this sample. 
When compared with the early and late pregnancy, more studies have been done 
in mid-pregnancy investigating the relationship between calcidiol and BG levels but there 
were inconsistent findings.  Most of these studies examined the relationship between 
calcidiol levels and a diagnosis of GDM, which is a condition of impaired glucose 
metabolism which, left untreated, leads to hyperglycemia in pregnancy.  For the purposes 
of this study, GDM was used as a proxy to hyperglycemia in pregnancy.  The time 
periods being studied varied, even though most were in the second trimester or mid-
pregnancy.  The method for the blood glucose level was inconsistent with some 
researchers using a fasting BG level, others using a BG level obtained after either a one-
step GDM screening test or others after a two-step GDM screening test.  The calcidiol 
levels used to define hypovitaminosis-D also varied in these studies.      
McLeod et al. (2011) examined a subset of the HAPO study and looked at the 
calcidiol level drawn concurrently as a fasting BG level at 24 to 32 weeks of gestation.  
They found calcidiol levels were inversely related to the fasting BG levels which 
suggests that glucose metabolism might be influenced by calcidiol.  Most of their 
participants were normoglycemic and there was an extremely low prevalence of 
hypovitaminosis-D in their sample because of subtropical location.  Zuhur et al. (2013) 
obtained serum calcidiol levels when testing for impaired glucose tolerance in pregnancy 
and found that only the pregnant women severely deficient for calcidiol (<12.5 nmol/L) 
were at risk for hyperglycemia.  
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Other researchers report an inverse association between mid-pregnancy calcidiol 
and BG at 24-28 weeks gestation.  Burris et al. (2012) found an inverse association 
between calcidiol levels and blood glucose levels at 26-28 weeks gestation.  They 
reported that women with severe calcidiol deficiency (serum levels <25 nmol/L) had a 
significantly increased risk of GDM.  Soheilykhah et al. (2010) and Zhang et al. (2008) 
found that hypovitaminosis-D in the second trimester was associated with a 2.66-fold 
increase in hyperglycemia at 24-28 weeks gestation.  Clifton-Bligh et al. (2008) found an 
inverse correlation between calcidiol levels and fasting BG when controlling for maternal 
BMI.  Maghbooli et al. (2008) defined hypovitaminosis-D as serum calcidiol <25 
nmol/L) with hypovitaminosis-D in 70.6% of the women which they report was 
associated with insulin resistance.  
The current study did not find evidence of a significant relationship between 
calcidiol drawn in mid-pregnancy (22-26 weeks gestation) and the BG level at 24-28 
weeks gestation when controlling for maternal age and BMI.  These findings were similar 
to those of Zuhur et al. (2013) who did not find a statistically significant relationship 
between deficient and insufficient levels of calcidiol and impaired glucose metabolism 
unless the hypovitaminosis-D was severe at < 12.5 nmol/L.  Similarly, Tomedi et al. 
(2013) did not find an association between calcidiol levels at < 16 weeks and 
hyperglycemia in non-smoking pregnant women.  As with the studies on calcidiol levels 
in early pregnancy, there was variation in the collection times for the calcidiol level, the 
definition of hypovitaminosis-D, and the method for obtaining the BG (fasting BG level 
versus a BG level obtained after either a one-step or a two-step GDM screening test).  
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The inconsistent findings across studies prevent conclusive evidence of the relationship 
between hypovitaminosis-D in mid pregnancy and BG levels at 24-28 weeks gestation. 
Relationship Between Calcidiol in Late Pregnancy and Blood Glucose 
Is there a correlation between the calcidiol level at 32-36 weeks gestation (late) 
and the BG level at 24-28 weeks gestation when controlling for the known confounding 
variables of age and BMI?  Two of the three participants with hyperglycemia at the GDM 
screening test also had hypovitaminosis-D at 32-36 weeks gestation (VitD-late) and one 
had adequate serum calcidiol at this third measurement point.  The relationship between 
calcidiol at 32-36 weeks gestation (VitD-late) and BG at 24-28 weeks gestation was 
analyzed, controlling for maternal age and BMI.  The R square was 0.075 which means 
the amount of variation explained by the model is 7.5%.  There does not appear to be a 
strong correlation between VitD-late and BG at 24-28 weeks gestation in this sample.  
This is consistent with the literature.   
Three other researchers reported on the relationship between calcidiol levels and 
BG levels in late pregnancy, but none of the calcidiol levels were obtained after 32 weeks 
gestation.  Since the current study examined the relationship between calcidiol levels at 
32-36 weeks of gestation and BG, this which limits application of the study findings.  For 
comparison, studies which examined the relationship between calcidiol levels in the third 
trimester of pregnancy and BG levels at mid-pregnancy were utilized.  Farrant et al. 
(2009) reported an inverse association between calcidiol levels at 30 weeks of gestation 
and the blood glucose level at a 30 minute glucose screening test.  Lau et al. (2011) found 
that lower serum calcidiol levels in the third trimester of pregnancy were independently 
associated with impaired glucose metabolism.  As noted above, McLeod et al. (2011) 
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found vitamin D levels were inversely related to fasting BG levels in samples drawn at 
the same time from participants between 24 to 32 weeks of gestation.  Based on the 
current science, there is no evidence of a statistically significant relationship between 
calcidiol levels in late pregnancy and BG levels in mid-pregnancy. 
Limitations 
This study examined the relationship between serum calcidiol levels at three 
points in pregnancy and the blood glucose level at mid-pregnancy.  There are several 
limitations to this study.  This was a correlation study and this type of research cannot 
prove causation by linking exposure to outcome for individuals.  It can, however, link the 
association by showing a positive or negative relationship between two variables, but this 
association does not prove causation (Grimes & Schultz, 2002).   
Research design was influenced by the review of the literature and use of a 
secondary analysis.  Secondary analysis is an efficient and cost effective research design 
but this method does have inherent restrictions because of the inability to change the 
sample size (McArt & McDougal, 2007).  It is possible that the size of the sample was 
inadequate to detect the effects of hypovitaminosis-D on glucose metabolism in 
pregnancy.     
The participants were drawn from a geographic location that is fairly homogenous 
in terms of socioeconomic status, ethnicity, and racial diversity.  The participants self-
selected by responding to the advertising and volunteering to be in the study.  The 
characteristics of pregnant women who volunteer for research studies compared to 
women who do not participate in research studies are unknown for this study.  Study 
criteria included English speaking so it is possible that participation was limited to less 
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diverse ethnic groups.  Participants also needed to be at least 18 years of age so a 
limitation was that the sample did not represent younger women of childbearing 
potential.  
The primary data set included additional information which was beyond the scope 
of this study.  The literature review informed the choice of variables known to influence 
the outcome of interest in this population.  Pre-pregnancy baseline serum calcidiol levels 
were not known.  The source of vitamin D intake (food, supplements, or exposure of 
unprotected bare skin to direct sunlight) was not included.  Factors such as season of the 
year, education level, marital status, and religion were not included and are a limitation of 
this study.  Although these factors were of interest, they are beyond the scope of the study 
reported here.  Other limitations of this study are discussed further in the concluding 
remarks. 
Calcidiol Testing Processes 
Laboratory results inform decision making therefore the accuracy and validity of 
the testing process is important.  Serum plasma calcidiol levels are a good biomarker for 
the status of vitamin D (van den Ouweland, Beijers, Demacker & van Daal, 2010); 
however, high variability has been reported in serum calcidiol measurements among 
laboratories (Binkley et al., 2004).  There are two main methods for determining calcidiol 
levels based either on competitive immunoassay or on chromatographic separation 
followed by direct detection through non-immunological means (Wallace, Gibson, de la 
Hunty, Lamberg-Allardt, & Ashwell, 2010).  Specificity is problematic for 
immunoassays due to the proportion of 25OHD2 when quantifying the proportion of 
calcidiol (Wallace et al., 2010). The methods using chromatography are more specific but 
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require expensive equipment, more labor intensive, and technically more difficult 
(Arneson & Arneson, 2013).  
All of the discrepancies led to a new program being established in 2011, the 
Vitamin D Standardization Program (VDSP).  The VDSP was formed under the 
combined efforts of the Center for Disease Control, National Institute of Health Office of 
Dietary Supplements, National Institute of Standards and Technology, the Belgian 
Laboratory for Analytical Chemistry, Ghent University, and the National Centre for 
Environmental Health (Enko, Kriefshauser, Stolba, Worf, & Halwachs-Baumann, 2015).  
It is anticipated that the work of the VDSP to standardize processes and emerging 
automated processes will also improve precision (Arneson & Arneson, 2013).   
The test used for the serum calicidiol levels for this study was the IDS 25-
Hydroxy Vitamin D EIA kit which uses an immunoassay method. The IDS EIA 
manufacturer reports the sensitivity for their test is with 5 nmol/L (Appendix D).  Care 
was taken to ensure accuracy in testing, however, the validity and reliability of serum 
calcidiol testing is problematic at this point in time.  The availability of consistent, 
specific, affordable methods is a limitation for studies involving serum calcidiol levels 
such as this one.  
Surprises 
There were two surprises which emerged from the current study.  The first was 
the statistically significant impact of BMI on serum calcidiol levels in early pregnancy.  
With the increasing rate of obesity in the United States, this finding highlights the need 
for awareness of possible hypovitaminosis-D during pregnancy when women who 
present for prenatal care have a higher BMI (Wang & Beydoun, 2007).  The second was 
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the lack of evidence of change in serum calcidiol levels when measured in early, mid, and 
late pregnancy in this study.  This is a surprise considering the focus on quality nutrition 
in pregnancy including taking a daily prenatal vitamin and adequate dietary intake.  
Hypovitaminosis-D may contribute to a poor foundation for life-long health therefore 
further research is needed to determine how to ensure women have adequate vitamin D in 
pregnancy (Kaludjerovic & Vieth, 2010).  These findings suggest that prenatal vitamins 
do not have adequate vitamin D.  They also suggest that women with a higher BMI who 
live in the upper Midwest should have a serum calcidiol level checked in early 
pregnancy. 
Conclusions 
The current study examined the relationship between vitamin D measured as 
serum calcidiol levels and the blood glucose levels in pregnancy.  This research examined 
the correlation between serum calcidiol and BG at three points during pregnancy.  The 
first was early pregnancy defined as 10-14 weeks gestation (VitD-early), the second was 
mid-pregnancy defined as 22-26 weeks gestation (VitD-mid), and the third was late 
pregnancy defined as 32-26 weeks gestation (VitD-late).  In each case, the confounding 
variables of maternal age and BMI calculated at the beginning of pregnancy were 
controlled for in the multiple regression analysis.  This study did not find a statistically 
significant relationship between serum calcidiol levels and blood glucose levels when 
controlling for the confounding variables of age and BMI at any of the three time points 
in pregnancy.    
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Implications for Action 
Application of nursing research is an essential component to improving health.  
The implications for action in response to the current study are presented here.  This 
begins with suggestions for nursing policy, is followed by recommendations for nursing 
education, and ends with application in nursing practice.  The implications for nursing 
research are in the section on recommendations for further research.   
Implications for Nursing Policy 
Nursing evaluates the client as a system to ensure optimal wellness according to 
the Neuman System Model (Neuman & Reed, 2007).  Protective internal and external 
mechanisms (known as Lines of Resistance) both stabilize and support the client system 
(Neuman, 2005).  The goal of nursing, according to the model, is to prevent or correct 
instability (Meleis, 2010) through nursing interventions which improve health.  The 
physiological stressors of pregnancy can lead to impaired glucose metabolism for some 
women.  Nursing has the potential to improve the health of pregnant women by advising 
them on the importance of vitamin D during pregnancy and recommending practices to 
attain adequate intake of vitamin D through food sources and taking a daily prenatal 
vitamin.  The scope of practice for the registered nurse includes assessment of client 
needs and education to meet those needs.  Giving the registered nurse the skills, 
knowledge and ability to prevent hypovitaminosis-D in pregnancy would be a reasonable 
application of the Neuman System Model and improve health of the population. 
Nurses are in a key position to influence decisions which improve health.  The 
findings of this study and similar studies demonstrate that hypovitaminosis-D may be a 
problem for many people in North Dakota.  Nurses can educate the public on the 
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importance of vitamin D for health and how to get adequate amounts.  Nurses can 
advocate for higher levels of vitamin D supplementation and calcidiol screening.  
Considering the high rates of hypovitaminosis-D, the population of pregnant women in 
this region should be considered at increased risk for deficiency and screened in early 
pregnancy for hypovitaminosis-D. 
Implications for Nursing Education  
Several implications which emerge from this research for nursing education.  
Theoretically, this is an example on how the environment affects the health of patients 
and demonstrates an application of the Neuman Systems Theory.  Nurses need to be 
aware of the importance of vitamin D within the internal environment of human body and 
also be knowledgeable on sources of vitamin D from exposure to sunlight, from diet, and 
from supplements (Brannon & Picciano, 2011; Specker, 2004; Tomedi et al., 2013; Ross 
et al., 2011).  Nursing curricula should include the unique nature of vitamin D as both a 
vitamin and prohormone along with the implications for health.  
Implications for Nursing Practice  
Nurses are in a unique position to influence the health of mothers and their 
offspring by teaching the prenatal patient about the importance of vitamin D.  With 
knowledge about what influences vitamin D status, the nurse can recommend testing or 
additional supplementation for women at risk for hypovitaminosis-D.  The nurse can 
identify expectant mothers who are at risk for hypovitaminosis-D and consult with the 
care team to optimize health for the women and their babies (Schroth et al., 2005). The 
nurse can educate patients about the importance of adequate vitamin D during pregnancy 
and inform the patients on how to safely obtain adequate vitamin D.  Women of 
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childbearing age could be informed of the potential health benefits that taking a 
supplement with the current recommended daily allowance of 600 IU of vitamin D prior 
to conception could improve serum calcidiol levels (IOM, 2011).  In addition, the 
findings of Ginde et al. (2010) demonstrate the need to recognize that pregnant 
adolescents (ages 13-19 years) were at increased risk for hypovitaminosis-D in pregnancy 
because they are more frequently are from a minority race, lower socioeconomic status, 
and not using any vitamin D supplements.  Nurses in practice can provide education and 
support to improve vitamin D status in this at risk group. 
Recommendations for Further Research 
Nurse scientists are in an ideal position to study health related outcomes such as 
calcidiol in pregnancy.  The importance of vitamin D beyond bone health is becoming 
increasingly apparent.  Recent work highlights the action of vitamin D on cell 
proliferation and is essential for maternal-fetal health during pregnancy and birth 
outcomes (Shin et al., 2010; Hollis & Wagner, 2013).  Unfortunately, the ethical concerns 
of conducting research on pregnant women limits studies in this population.  Careful 
design must ensure no harm to either the woman or the fetus.  There is a need for 
rigorous intervention trials to determine if vitamin D supplementation for pregnant 
women with hypovitaminosis-D status decreases the risk of hyperglycemia (Alzaim & 
Wood, 2013; Baker et al., 2012; Joergensen et al., 2014; McLeod et al., 2011; Pittas & 
Dawson-Hughes, 2010; Senti et al., 2013).  The conflicting results on the relationship 
between hypovitaminosis-D and glucose metabolism in pregnancy creates an opportunity 
for nurse researchers to contribute to the science that can improve health.   
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These findings suggest that epidemiological studies are needed to better 
understand the regional implications of hypovitaminosis-D due to latitude, lifestyle, and 
culture.  There is a need for public health studies on rates of hyperglycemia in pregnancy 
and comprehensive rates of GDM beyond the HAPO studies, especially because of the 
implications for the lifelong health of the offspring.  Since a pattern of hypovitaminosis-
D has been shown from various small studies at higher latitudes, larger studies are needed 
to determine the prevalence of vitamin D deficiency in such populations.  Finally, there is 
a need to investigate the relationship between calcidiol and hyperglycemia in pregnancy 
using a larger population with a greater variance in calcidiol and glucose levels.  
Concluding Remarks 
There are several possible reasons for results in this study.  First, there may not be 
an association (causal relationship) between hypovitaminosis-D and hyperglycemia in 
mid-pregnancy.  The high prevalence of hypovitaminosis-D in the study participants did 
not provide enough variation to show a difference if one does exist.  The research design 
was an analysis of an existing data set which precluded increasing the sample size.  
Participant characteristics closely represented the region where the participants resided 
but were not representative of the nation.  This limits the generalizability of the findings.   
The findings of this study are consistent with the professional literature 
demonstrating the hypovitaminosis-D in pregnancy is widespread and a public health 
concern (Alzaim & Wood, 2013; Tande et al., 2013; Zuhur et al., 2013).  A limitation of 
this study is that dietary intake and vitamin use was not included in the outcome.  
Presumably, a majority of pregnant women would be taking a prenatal vitamin because 
this is fairly normal behavior in pregnancy.  If that assumption is true, the high incidence 
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and severity of hypovitaminosis-D is alarming.  The women in this study were aware 
they were pregnant in the first trimester because they were enrolled in the study prior to 
14 weeks gestation and the sample was representative of the population, consistent in 
terms of disease burden and ethnicity in the population of interest. 
There was no evidence of a statistically significant relationship between the serum 
calcidiol levels in early, mid, or late pregnancy and the BG level at mid-pregnancy in this 
investigation.  This research contributes to the science by demonstrating that serum 
calcidiol levels collected in at three different points in pregnancy which were mostly 
below 75 nmol/L were not associated with hyperglycemia at 24-28 weeks gestation in 
pregnancy.  The studies reported in the literature shows inconsistent findings on the 
relationship between calcidiol and BG in pregnancy.  A need exists for randomized 
controlled trials to determine the effect of vitamin D supplementation on glucose 
homeostasis during pregnancy (Fanos, Vierucci & Saggese, 2013; Joergensen et al., 
2014; Olmos-Ortiz et al., 2015; Senti, Thiele & Anderson, 2013).  There is also a need 
for further research to generate a body of evidence to determine if a change in the daily 
recommended intake of vitamin D is needed to ensure adequate serum calcidiol levels in 
pregnancy. This research has the potential to benefit women and offspring both during 
pregnancy and for lifelong health. 
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